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The asymmetric synthesis of spirolide C, a highly potent marine toxin, has been investigated in 
our laboratory.  The construction of C7-C28 bis-spiroketal was completed through a strategy 
utilizing an intermolecular Stetter reaction and a biomimetic ketalization process.  Stereocenters 
were set in great diastereo- and enantioselectivity via asymmetric catalysis.  The efficiency of the 
synthesis was demonstrated by its convergency and high yields.  
 
A cinchona alkaloid catalyzed ketene-oxaziridine cyclocondensation has been developed 
to provide an access to enantioenriched α-hydroxy carbonyl compounds.  The oxazolidinones 
arising from the cyclocondensation were converted to various α-hydroxy carbonyl compounds 
via nucleophilic ring openings.  Greater than 98% ee was achieved in oxazolidinone formation 
and the subsequent ring openings proceeded with retention of the ee or minor epimerization. 
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1.0  INTRODUCTION 
1.1 BIOLOGICAL ACTIVITIES AND STRUCTURE FEATURES 
Cyclic imine phycotoxins are an emerging class of marine toxins characterized by their fast 
acting toxicity,
1
 including spirolides 1 (Figure 1),
2
 gymnodimines 2,
3
 pinnatoxins 3,
4
 pteriatoxins 
4,
5
 and spiro-prorocentrimines 5 (Figure 2).
6
  These natural products are macrocyclic compounds 
with imine and spiro-linked ether moieties, exhibiting similar toxicity in the intraperitoneal 
mouse assay.
1
 The imine group functions as their common pharmacophore.
7
 The major source of 
these toxins is unicellular algae.  A specific example is the dinoflagellate Alexandrium ostenfeldii 
which produces spirolides.
2
  These toxins pose a potential threat to human health, especially to 
people living in the coastal areas, as they can move up the food chain through shellfish and other 
seafood.
8
  In order to enhance the safety of consumers, studies of the chemical structure, identity, 
and mechanism of action of these toxins are necessary. 
 2 
 
Figure 1. Structures of spirolides A-D 
 
 
Figure 2. Representative examples of other cyclic imine phycotoxins 
 
 3 
Spirolides (A-D) (Figure 1) were first isolated in 1995 by Hu and co-workers from 
shellfish extracts harvested from the south-eastern coast of Nova Scotia in Canada.
9
  There have 
been 14 members of spirolides reported to date.  Spirolides contain an unusual 5,5,6 bis-
spiroketal moiety embedded within a 23-membered all carbon macrocycle along with a 6,7-
spirocyclic imine structure that is also present in related gymnodimines, pinnatoxins and 
pteriatoxins.  Given the structural complexity, it has been extremely challenging to establish the 
total configuration based on spectroscopic data.  The relative stereochemistry of 13-desmethyl 
spirolide C (6), except for the stereogenic center at C4, was elucidated in 2001 by means of 
NMR analysis and molecular modeling.
10
 The relative stereochemistry of spirolides B and D 
were also determined by comparison of their NMR data with 13-desmethyl spirolide C.  The 
relative stereochemistry at C4 remained unknown until 2009 when it was assigned in the 13,19-
didesmethyl spirolide C (7) via computational studies.
11
  Despite the extensive structural 
analysis, a stereoselctive synthesis of spirolides is still required to confirm the structure 
unambiguously.  To date, the total synthesis of any member in the spirolide family has not been 
reported, but the syntheses of the 5,5,6 bis-spiroketal of spirolides B and D have been 
accomplished by Ishihara
12
 and Brimble.
13
  Studies on the 6,7-spiroimine moiety are ongoing in 
the Zakarian group.
14 
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Figure 3. Relative stereochemistry of 6 and 7 
 
Spirolides are toxic to mice by intraperitoneal injection, with spirolide C having an LD50 
value of 8.0 μg/kg.15  The mechanism of action is believed to be interfering in the action of 
certain neurotransmitters based on two main characters of the toxic effects.
1
  Rapid expression of 
neurological symptoms appears in a few minutes after intraperitoneal administration in mice.  
Death occurs within 20 min under the lethal dose, otherwise the mice experiencing full recovery.  
 
 
Figure 4. Structure of the spirolide-AChBP complex (graphic from Bourne, Y. et al. Proc. Natl. Acd. 
Sci. 2010, 107, 6076-6081) 
 
 5 
Further studies revealed that the neurotoxicity of spirolides is due to the inhibition of both 
the nicotinic and muscarinic acetylcholine receptors in the nervous system.
16
  As the nicotinic 
acetylcholine receptor surrogates, spirolides exhibit picomolar affinity to acetylcholine-binding 
proteins (AChBP).
8
  The diffusion-limited association with AChBP and slow dissociation thereof 
account for the irreversible binding mode of spirolides.  Crystal structure (Figure 4) of 13-
desmethyl spirolide C 6 bound to AChBP illustrated the molecule neatly imbedded within the 
pocket which accommodated acetylcholine under physiological conditions.  Hydrogen bonding 
of the protonated imine group in spirolides with the carbonyl oxygen of loop C Trp147 placed 
the toxin in the center of the pocket.  The complementarity of the bis-spiroketal moiety and the 
interface of the protein further contributed to the high affinity.
8
  The importance of the 
spiroimine unit to the toxicity was further confirmed during the investigation of spirolide 
derivatives (Figure 5).  When the imine moiety was reduced to secondary amine 8, this 
compound showed very mild toxicity.
17 
 The keto-amine hydrolysis derivatives, spirolides E 9 
and F 10, were completely nontoxic.
17
   
 
 
Figure 5. Spirolides lacking the imine moiety showed reduced toxicity 
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1.2 PREVIOUS STUDIES IN THE SYNTHESIS OF SPIROLIDE C 
Previous studies in the synthesis of spirolide C (1) have been reported by Ishihara,
12
 Brimble,
13
 
and Zakarian.
14
  Ishihara and Brimble synthesized the 5,5,6 bis-spiroketal fragment, although via 
different strategies.  Instead of targeting the bis-spiroketal, Zakarian’s synthesis commenced with 
constructing the substituted cyclohexene with the stereocenters set by a diastereoselective 
Ireland-Claisen rearrangement.  His approach was inspired by the success in the total synthesis 
of pinnatoxin A 3 (Figure 2),
18
 which has a homologous structure to spirolide C (1).  Despite 
continuing efforts towards the total synthesis for over a decade, there has been no complete 
synthesis of spirolide C reported to date or of other members in the spirolide family. 
In 2004, Ishihara accomplished the synthesis of the bis-spiroketal moiety in spirolide C 
(Scheme 1).  The tricyclic framework was constructed by a one-step ketalization of the acyclic 
triketone 15.  This triketone 15 was obtained by ruthenium oxide catalyzed oxidation of the 
alkyne precursor 14.  This alkyne could be accessed via a sequence of nucleophilic addition of α-
sulfonyl anion 12-Li to the aldehyde 13, desulfurization and oxidation of the resultant secondary 
alcohol.  Upon removal of the TBS ether with HF·pyridine, the ketalization took place under the 
same conditions to give the desired tricyclic compound 16a and its C15 epimer 16b as a 1:4 
mixture.  Interestingly, the subsequent methyl lithium addition and TBS protection of the 
intervening tertiary alcohol afforded the bis-spiroketals (11a and 11b) of different diastereomeric 
ratio (2:1), favoring the desired configuration as in spirolide C.  The author rationalized the shift 
of equilibrium was due to a change of ground state energy differences between these two 
silylated isomers as a result of breaking the hydrogen bonding interactions.
12
     
 7 
Scheme 1. Ishihara’s synthesis of bis-spiroketal 
 
 
The Brimble group exploited an oxidative radical cyclization methodology to build the 
bis-spiroketal fragment 17 towards the synthesis of spirolide C (Scheme 2).
13
 The cyclization 
precursor 20 was obtained as a 1:1 mixture of diastereomers by a Barbier reaction of 
dihydropyran 19 with aldehyde 18.  Irradiation of 20 in the presence of iodobenzene diacetate 
and iodine gave spiroketal 21 which upon removal of the silyl ether was subjected to a second 
oxidative radical cyclization, providing the bis-spiroketal 22 as a 1:1:1:1 mixture of 
diastereomers.  Treating this 1:1:1:1 mixture with m-CPBA, surprisingly, gave the epoxide 23 as 
a single diastereomer.  The presence of m-chlorobenzoic acid and water in m-CPBA presumably 
facilitated the equilibration to the thermodynamically most favored isomer 23.  Epoxide 23 
underwent regioselective ring opening with DIBAL-H, and the resultant alcohol was oxidized 
 8 
upon exposure to Dess-Martin periodinane.  Stereoselective axial addition of methylmagnesium 
bromide to the ketone afforded tertiary alcohol 17, however, with the undesired configuration 
(trans).  The trans stereochemistry of 17 was determined by nOe analysis.   
 
Scheme 2. Brimble’s synthesis of bis-spiroketal 17 
 
 
As stated before, Zakarian and his co-workers initiated the synthesis of spirolide C by 
constructing the substituted cyclohexene which would later become the spiroimine unit in the 
natural product (Scheme 3).  Following the similar strategy as in the study of pinnatoxin A, 
where the author utilized an Ireland-Claisen rearrangement for the assembly of the spiroimine 
unit, they planned to employ the same transformation to set the vicinal stereocenters (C7 and C29) 
in spirolide C.  In the forward sense, the rearrangement precursor 26 was generated in favor of 
the E enolate via stereoselective enolization of 27 using chiral lithium amide (S)-28-Li.  The 
ensuing Ireland-Claisen rearrangement proceeded with great diastereoselectivity to give 25.  
Upon converting the resultant carboxylic acid to the corresponding pivaloate 29, the olefin 
functionality was transformed to the secondary alcohol 30 by ozonolysis and subsequent 
 9 
metylmagnesium bromide addition.  Double oxidation of the diol 30 to the keto aldehyde set the 
stage for an aldol cyclocondensation, which was accomplished in the presence of piperidinium 
trifluoroacetate, affording the cyclized compound 24 to complete the synthesis of the substituted 
cyclohexene 31.
14a
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Scheme 3. Zarkarian’s synthesis of the cyclohexene ring 31 
 
 
Zakarian planned to utilize a ring-closing metathesis (RCM) to close the macrocycle prior 
to assembling the bis-spiroketal in spirolide C (Scheme 4).
14b
  To this end, the aforementioned 
cyclohexene 31 was advanced to 32 in 15 steps.  Iodide 34 was prepared from 33 in 18 steps.  A 
direct addition of the alkyl lithium reagent 34-Li, generated by lithium-iodine exchange from 
 11 
iodide 34, with aldehyde 32 afforded coupled product 35a after Dess-Martin oxidation and 
desilylation.  Extensive studies on the key RCM reaction were performed using compounds 35a, 
35b and 35c as the substrates and Hoveyda-Grubbs II 36 or Grubbs II 37 as the catalyst.  In all 
cases, the RCM reaction proceeded very sluggish at 40 °C, leading to less than 10% conversion 
to the desired macrocycle 38.  Increasing the reaction temperature to 90 °C resulted in complete 
decomposition.  The lack of reactivity of the substrates was presumably attributed to the steric 
bulk around the two terminal olefins.  In response, spiroketal 39 was employed in the RCM 
reaction, under the hypothesis that a more compact substrate would grant greater reactivity.  
Indeed, subjecting 39 to the optimized conditions (Grubbs II 30 mol%, 1,2-dichloroethane, 60 
°C, 24h) afforded macrocycle 40 in an improved yield (24%), however, still inadequate for 
continuing the synthesis of spirolide C. 
 12 
Scheme 4. Studies on RCM reactions to construct the macrocycle of spirolide C  
 
 
In conclusion, spirolides, isolated 15 years ago, still represent an active area of research 
in both synthetic chemistry and biology.  The total synthesis of spirolides remains a challenge to 
date, despite impressive progress in these aforementioned partial syntheses.  The low natural 
abundance of spirolides currently hampers efforts towards pharmacological evaluation, and 
 13 
possible medicinal applications.  Therefore, an efficient stereoselective synthesis of spirolide C is 
of great importance. 
1.3 RETROSYNTHETIC ANALYSIS OF SPIROLIDE C 
Our retrosynthesis of spirolide C 1 aims at high convergency and limited functional group 
manipulations to achieve atom economy and synthetic efficiency (Scheme 5).  The butenolide 
subunit 41 will be installed at the last step through a metal-mediated coupling reaction after 
closing the macrocycle 42.  The macrocyle will be constructed via an intramolecular iminium ion 
Diels-Alder reaction between a conjugated triflic enolate and the dieneophile component located 
at the top half of the molecule 43.  Compound 43 can be further dissected via a Liebeskind 
coupling
19
 into vinyl stannane 40 and densely functionalized bis-spiroketal 45.  We propose a 
biomimetic ketalization
20
 to generate the bis-spiroketal 45 from acyclic precursor 46 under 
thermodynamic control.  Compound 46 will be joined by two fragments (47 and 48) having 
comparable complexities through an intermolecular Stetter reaction.  Utilizing an intermolecular 
Stetter reaction for fragment coupling is one of the key features of our synthesis, and such a 
transformation has not been implemented in the context of complex molecule synthesis.  We 
reported herein the completion of bis-spiroketal 45. 
 14 
Scheme 5. Retrosynthesis of spirolide C 
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2.0  COMPLETION OF THE C7-C28 BIS-SPIROKETAL 
2.1 SYNTHESIS OF THE ENONE FRAGMENT 
Our investigation commenced with constructing enone fragment 47 as illustrated in Figure 6.  
Our primary goal was to generate an efficient route where the requisite stereocenters would be 
established via asymmetric catalysis from achiral starting materials.  To this end, it was decided 
to set the C22 stereocenter by attaining the enantioenriched β-lactone 49 via the acyl halide-
aldehyde cyclocondensation (AAC) from aldehyde 50 and acetyl bromide.
21  β-Lactones can 
undergo amine-based nucleophilic ring opening to deliver products that are the functional 
equivalent of amide aldol adducts.
22
  Based on this reactivity pattern, we decided to convert β-
lactone 49 to the requisite ketoester 47 via nucleophilic attack of organozinc reagent 51 to 
accomplish the C24-C25 bond construction.  In order to introduce the C19 stereocenter, we planned 
to utilize a Sharpless asymmetric dihydroxylation
23
 on the C18-C19 olefin. 
 
 16 
 
Figure 6. Retrosynthesis of the enone fragment 47 
 
Following the retrosynthesis mentioned above, we initiated our investigation with a 
Lewis acid catalyzed AAC reaction between aldehyde 50 and acetyl bromide (Scheme 6).  
Utilizing Al(III)-triamine complex 54 as the catalyst, aldehyde 50 underwent cyclocondensation 
with the in situ-generated ketene arising from acetyl bromide to produce β-lactone 49 (91%, 
>98% ee).  We planned to ring open the β-lactone with organozinc reagent 51 based on literature 
precedent.  Knochel has demonstrated that functionalized organozinc reagents, such as 51, can 
add to aromatic aldehydes and ketones effectively in the presence of MgCl2.
24
  Employing 
Knochel’s protocol, ethyl 4-bromobutanoate 53 was reacted with magnesium powder in a THF 
solution of ZnCl2 and LiCl at 25 °C for 1.5 h to generate 51.  Exposing β-lactone 49 to 51 at 
ambient temperature overnight, however, only provided halogenated carboxylic acid 55 in 52% 
yield but none of the desired ketoester.  It was reasoned that the carbon nucleophile 51 was 
unreactive to add into the β-lactone while the halogen anion (Br− or Cl−) in the reaction system 
underwent nucleophilic ring opening to give 55, a reactivity that has been observed with azide 
and sulfonamide anion nucleophiles.
22
  Based on this result, we needed to identify a more 
reactive carbon nucleophile to accomplish the desired lactone-to-ketoester conversion. 
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Scheme 6. AAC reaction and initial attempts at converting the β-lactone to the ketoester 
 
 
We then decided to employ a two-step approach to construct the ketoester utilizing a 
more reactive organolithium rea 
gent as the nucleophile (Scheme 7).  First step involved converting β-lactone 49 to 
Weinreb amide 57 which was accomplished though nucleophilic attack of MeON(Me)AlCl2 56 
followed by silylation of the intervening secondary alcohol (94%, two steps).  The requisite 
organolithium reagent 60 was prepared according to Corey’s protocol.25  An initial 
rearrangement of 58 to 59 took place in the presence of catalytic BF3·OEt2 and the subsequent 
lithium-halogen exchange occurred upon treating 59 with 
tBuLi at −78 °C.  This in situ-
generated organolithium reagent 60 underwent nucleophilic attack at the carbonyl of 57 to 
produce the corresponding keto-orthoester 61 (−78 °C, 3h).  Rapid hydrolysis of crude 61 was 
 18 
accomplished under acidic conditions (0.1 equiv of PPTS, MeOH:H2O=32:1, ambient 
temperature) and the ensuing methanolysis was carried out in a one-pot fashion by introducing 
Cs2CO3 (2 equiv) in the reaction mixture to afford the desired ketoester 62 (85%, three steps).  
The nature of the base was critical to allow for clean transesterification, as switching to less 
expensive K2CO3 led to fast β-elimination of the TBS ether.  This was proved by the isolation of 
both enone 63 and β-methoxy ketone 64 byproducts. 
 
Scheme 7. Revised synthesis of the ketoester 
 
 
Having accessed ketoester 62, we set out to install the C19 tertiary alcohol via Sharpless 
asymmetric dihydroxylation (SAD).
23
  Under the typical SAD conditions, treating 62 with AD-
mix-β in 1:1 t-BuOH/H2O provided diol 65 in 98% yield as a single diastereomer determined by 
13
C NMR (Eq 1).  The absolute configuration of C19 was assigned (R) according to the 
 19 
mnemonic device developed by Sharpless and co-workers.
23
  The excellent diastereoselectivity of 
the dihydroxylation was surprising given that 1,1-disubstituted olefins typically show reduced 
selectivity due to lack of steric bias.
26
  
 
 
 
In order to complete the synthesis of fragment 47, we utilized an oxo ammonium 
oxidation
27
 to convert the primary alcohol in 66 to an aldehyde and then perform a Grignard 
addition and a Dess-Martin oxidation to finalize the enone (Scheme 8).  In the event, treating 65 
with catalytic 2,2,6,6-tetramethylpiperidine (TEMPO), KBr, and NaOCl solution afforded 
aldehyde 66 upon silylation of the tertiary alcohol with TMSOTf (90% yield, two steps).  The 
exact stoichiometry of NaOCl (1.0 equiv) was crucial to avoid substantial over-oxidation of 65.  
In the presence of excess oxidant, triketone 67 was isolated as a byproduct, presumably via 
pinacol rearrangement of 68 and oxidation of the resulting secondary alcohol 69.  
Chemoselective Grignard addition of vinylmagnesium bromide took place at the aldehyde (77%) 
and the secondary alcohol thus obtained was treated with Dess-Martin periodinane to give the 
targeted enone fragment 47 (70%).  This enone was stored in benzene at −25 °C with a crystal of 
2,6-di-tert-butyl-4-methylphenol (BHT) to prevent polymerization.  
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Scheme 8. Complete the enone synthesis and possible over oxidation 
 
 
2.2 EXPLORATORY SYNTHESIS OF THE ALDEHYDE FRAGMENT 
With the synthesis of enone fragment 47 completed, our next step was to access aldehyde 48 that 
would be joined with 47 to construct the carbon back bone of the bis-spiroketal in spirolide C.  
Our initial plan of introducing the three stereocenters in 48 was to prepare enantioenriched β-
lactone 70 via two consecutive AAC reactions (Scheme 9).
21a
 The following structure 
modifications of 70 would involve insertion of a methylene group between C13 and C14 and 
elaboration of the alkyne group to a trisubstituted olefin. 
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Scheme 9. Initial plan for the aldehyde fragment synthesis 
 
 
Our synthesis began with a Lewis base-catalyzed AAC reaction to attain enantioenriched 
β-lactone 71 (Scheme 10).  Utilizing TMSQd 73 (10 mol %) as the catalyst and MgCl2
 
(1.0 
equiv) as the Lewis acid, aldehyde 72 underwent cyclocondensation with acetyl chloride at −78 
°C to afford β-lactone 71 (90%, >98% ee).  The excellent enantioselectivity was achieved by 
going through the closed transition state 74.
28
  We then employed a one-pot procedure to ring 
open 71 and protect the resulting secondary alcohol.  Nucleophilic attack of ethane thiol 
catalyzed by KHMDS (0.1 equiv) yielded the secondary alcohol that was trapped by in situ 
silylation with TBSOTf to give thioester 75 in 93% yield.  Thioester 75 was then reduced to 
aldehyde 76 with DIBAL-H (92%), setting the stage for a second AAC reaction.   
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Scheme 10. Early stage of the aldehyde fragment synthesis 
 
 
In comparison to the aforementioned AAC reaction of 72 (Scheme 10), the 
cyclocondensation of aldehyde 76 with propionyl chloride required more experimentation to 
reach a satisfactory result (Table 1).  Compared to 72, aldehyde 76 was anticipated to show 
diminished reactivity in the AAC reaction due to steric bulk imposed by the OTBS group.  In 
response, we chose a stronger Lewis acid (LiClO4) to facilitate the reaction by increasing the 
electrophilicity of 76.  When using two equivalents of LiClO4 and 10 mol % of TMSQd, 
cyclocondensation between 76 and propionyl chloride only afforded a modest yield of 40% 
(Entry 1).  The β-lactone product 70 was contaminated by inseparable impurities containing silyl 
groups (TBS and TMS) identified by 
1
H NMR.  The structure of the impurities remained elusive 
though.  We attributed this impurity formation to a retro-aldol process of aldehyde 76 under the 
influence of excess Lewis acids.  In order to suppress this unproductive retro-aldol without 
retarding the desired cyclocondensation, we decided to lower the stoichiometry of the Lewis acid 
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to 0.3 equivalent while increase the catalyst loading (TMSQd) to 20 mol %.  As a result, the 
reaction became much cleaner but the conversion of the aldehyde dropped to 60%, resulting in a 
lower yield (32%) (Entry 2).  Eventually, switching to a more reactive catalyst, O-
methylquinidine (MeQd, 20 mol %),
28
 in combination with LiClO4 (0.5 equiv) gave β-lactone 70 
in 65% yield as a 5.6:1 inseparable mixture of diastereomers.  The moderate diastereoselectivity 
was attributed to the mismatched nature of the catalyst and substrate with respect to stereocontrol 
(Figure 7).  Evans has shown that β-oxygenated aldehydes 77 inherently favored a 1,3-anti-
relationship between the newly formed hydroxyl group and the pre-existing one (79).
29 
 
Table 1. Optimization of the AAC reaction of 76 to 70 
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Figure 7. Evans’ model for substrate-controlled 1,3-diastereoselectivity 
 
To complete the fragment synthesis, we needed to convert the β-lactone functionality of 
70 to a one carbon homologated aldehyde and also transform the TMS alkyne to a trisubstituted 
olefin.  To achieve these goals, we treated 70 with DIBAL-H at −50 °C to afford reductive ring 
opening and isolated diol 80 as a single diastereomer after flash column chromatography.  
Iodination of the primary alcohol took place upon exposing 80 to I2 and triphenylphosphine 
(91%).  After silylation with TESOTf, iodide 81 was subjected to a SN2 reaction with sodium 
cyanide (DMSO, 60 °C) to give 82 (74%).  Selective deprotection of the TMS alkyne with 
K2CO3 in MeOH at ambient temperature gave 83 in 82% yield.  It was initially planned to use 
the zirconium catalyzed carboalumination chemistry
30
 to install the methyl group on the alkyne.  
However, a model study dismissed this strategy due to no reaction or decomposition occurring at 
extended reaction time (Figure 8).  We attributed the observed lack of reactivity of 84 to the 
bulky TBS ether that interfered with the coordination of the triple bond to the zirconium metal 
center and such coordination is required for effective carbon-metal addition.
31 
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Scheme 11. Structural modification of β-lactone 70 
 
 
 
Figure 8. Attempted model studies on the carboalumination 
 
We next pursued an alternate method, copper-mediated conjugated addition, to covert 
alkyne 83 to a trisubstituted olefin.
32
  This time we focused on utilizing the activated alkyne 86 
as the substrate (Scheme 12).  Alkyne 86 was prepared by deprotonating 83 with 
nBuLi (−78 °C) 
followed by in situ acylation with isopropyl chloroformate 85 (32%).  The modest yield was 
attributed to unproductive addition of 
n
BuLi to the nitrile group in 86, evidenced by the isolation 
of 92 (22%) after hydrolysis.  The following conjugated addition proceeded smoothly upon 
exposing 86 to the in situ-generated cupric reagent 87 from MeMgBr and CuI (2:1) to yield 88 
(65%).  Double reduction of the nitrile and the ester groups in 88 was achieved by employing 3.0 
equivalents of DIBAL-H at −50 °C, albeit in modest yield (40%).  We then decided to protect the 
primary alcohol 88 as PMB ether.  Considering the aldehyde functionality is sensitive to strong 
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base conditions, we chose mild acid-catalyzed conditions to form the PMB ether.  Exposing 89 
to PMB-acetimidate 90 and pyridinium p-toluenesulfonate (PPTS) overnight provided 91 as the 
major product (crude 
1
H NMR), however, only led to 16% isolated yield after flash column 
chromatography.  We assumed that aldehyde 91 was sensitive to silica gel and prone to 
decomposition during the course of separation.  Overall, it took 14 steps to synthesize aldehyde 
fragment 91 in 0.23% yield from commercially available starting materials.  The lack of 
efficiency of this route prompted us to pursue an alternative one to 91. 
 
Scheme 12. Complete the synthesis of the aldehyde fragment via AAC approach 
 
 
2.3 FINALIZED ROUTE TO THE ALDEHYDE FRAGMENT 
The previous synthesis of the aldehyde fragment displayed the efficacy of our AAC chemistry to 
construct stereocenters, however, modest yields were encountered in the conversion of an alkyne 
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to a trisubstituted olefin as well as the PMB protection in the last step.  If we could integrate the 
trisubstituted olefin and the PMB group in the starting material 93 (Figure 9), we would be able 
to avoid these low-yielding structural modifications and ultimately increase the overall synthetic 
yield.  Following the literature procedure, aldehyde 93 was prepared in decagram quantity (78%, 
four steps).
33
  Unfortunately, attempted AAC reactions of 93 under Lewis acid- or Lewis base-
catalyzed conditions proved futile with only recovery of 93 (Figure 9).  Instead, we decided to 
use a Keck-type allylation reaction
34
 followed by an asymmetric Brown crotylation
35
 to set the 
requisite stereocenters (Scheme 13).  The resulting terminal olefin in 96 could be converted to an 
aldehyde by a hydroboration-oxidation sequence.   
 
 
Figure 9. Modified starting material and attempted AAC reactions 
 
Scheme 13. New strategy to establish stereocenters in the aldehyde fragment 
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The asymmetric allylation of aldehyde 93 was executed by following Maruoka’s 
procedure (Scheme 14).
34
  Maruoka and co-workers disclosed a Keck-type enantioselective 
allylation catalyzed by Ti(IV)-BINOL complex 97.  In the presence of 97 (20 mol %), aldehyde 
93 was reacted with allyltributylstannane 98 at 0 °C to produce chiral carbinol 95 (86%, 94% ee).  
Upon silylation of 95 with TBSOTf (89%), we employed a dihydroxylation-oxidative cleavage 
sequence to access aldehyde 99 (80%, two steps).
36
  Chemoselective dihydroxylation at the 
terminal olefin was achieved by utilizing 1.0 equivalent of NMO and keeping the reaction 
temperature at 0 °C, as the internal olefin is deactivated to the dihydroxylation by the steric 
hindrance.   
 
Scheme 14. Keck-type asymmetric allylation catalyzed by Ti(IV)-BINOL complex 97 
 
 
To complete the fragment synthesis, an asymmetric Brown crotylation
 
was utilized to set 
the other two stereocenters required in aldehyde fragment 48 (Scheme 15).
35
  Treating 99 with 
the in situ-generated crotyl-(−)-Ipc-borane afforded 101 after 3h at −78 °C as a 6:1 mixture of 
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diastereomers (73%).  The major diastereomer was confirmed to have the desired 
stereochemistry by nOe analysis after converting 101 to the acetonide derivative 102.
37
  We 
observed a strong signal between the Ha and Hb in the NOESY spectrum, indicating a syn 
relationship between the alkoxy groups.  It is noteworthy that the diastereoselectivity (6:1) in the 
crotylation reaction is comparable to the previous AAC approach (5.6:1).  Upon silylation of this 
diastereomer mixture with TBSOTf (100%), chemoselective hydroboration (9-BBN) of the 
terminal olefin in 103 and the subsequent Dess-Martin oxidation of the intervening alcohol 
delivered aldehyde fragment 48 which was isolated as a single diastereomer after flash column 
chromatography (80%, two steps).  This optimized route only required eight steps, leading to an 
enhanced overall yield of 36%.  
 
Scheme 15 Asymmetric Brown crotylation and completion of the fragment synthesis 
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2.4 COUPLING THE ENONE AND THE ALDEHYDE FRAGMENTS 
Constructing the carbon back bone of the bis-spiroketal moiety in spirolide C required joining 
the enone and the aldehyde fragments by attaining a 1,4-dicarbonyl connectivity.  The Stetter 
reaction rose as a proper strategy.  Since the seminal work of Stetter in 1973, the N-heterocyclic 
carbene (NHC)-catalyzed addition of aldehydes to Michael acceptors, the Stetter reaction, has 
been widely used as a catalytic method for the synthesis of 1,4-dicarbonyl and related 
compounds.
38,39
 The significance of this transformation lies in the capacity of generating an 
“unnatural” functional group distance, which is difficult to accomplish using traditional methods.  
In the catalytic cycle, aldehyde 105 is activated by carbene 108 under generation of the Breslow 
intermediate 110 (Scheme 16).
40
  This acyl anion equivalent 110 undergoes nucleophilic attack 
to the Michael acceptor 104 that is followed by regeneration of catalyst 108 to produce the 1,4-
dicarbonyl product 106. 
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Scheme 16. The Stetter reaction and its mechanism 
 
 
           Despite extensive studies in this area, the intermolecular Stetter reaction has been rarely 
utilized on complex molecules in a natural product synthesis.  There are several limitations that 
restrain its synthetic utility.  The competing side reaction, benzoin condensation,
40
 is inevitable 
and excess aldehyde is typically required to achieve an appreciable yield of the Stetter product 
(Figure 10).  In the case of late-stage fragment coupling, superstoichiometry of one coupling 
partner will drastically diminish the efficiency of the entire synthesis.   Further, when using 
unreactive aliphatic aldehyde, reactions require forcing conditions, such as prolonged time, 
elevated temperature and excess bases, which are not compatible with diverse functional groups.  
Despite these disadvantages, the Stetter reaction possesses compelling features for us since it 
allows for direct access to the 1,4-dicarbonyl connectivity and after the next acid-mediated 
ketalization step, we can establish the required bis-spiroketal scaffold in a total of two steps from 
the enone and the aldehyde fragments.   
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Figure 10. Benzoin condensation 
 
To initiate the study of the fragment coupling, we started with the thiazolium-based NHC 
catalyst 114 due to its rich history in the Stetter transformation (Scheme 17).
38
  Refluxing a 
mixture of catalyst 114 (0.9 equiv), enone 47 (1.0 equiv), aldehyde 48 (3.0 equiv), and Et3N (6.0 
equiv) in EtOH for 16h afforded the coupled product 115 in 35% yield.  Along with 115, we also 
isolated the benzoin condensation product 116 (25%) as well as byproduct 117 (28%) arising 
from air oxidation of 48 catalyzed by 114.
41
  Despite the modest conversion, enone 47 was 
consumed completely according to the crude 
1
H NMR, indicating its limited stability under the 
reaction conditions.  Such instability of 47 was further confirmed by its rapid polymerization 
even at low temperature, forming an opaque white plastic.  Seemingly, if the desired Stetter 
reaction proceeded at a slow rate, the polymerization of the enone would deplete the active 
monomer and as a result, aldehyde 48 would be consumed by either benzoin condensation or air 
oxidation.  Therefore, in order to improve the yield, we needed to identify a more reactive and 
selective catalyst for the Stetter reaction. 
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Scheme 17. Initial attempts at the Stetter reaction utilizing thiazolium-based catalyst 114 
 
 
Our next choice of catalyst was Rovis catalyst 118
42
 (Figure 11), based on its efficacy 
demonstrated in Nicolaou’s synthesis of Lomaiviticin aglycon.  Nicolaou and co-workers 
identified 118 as an active catalyst for a late stage ring construction by  way of a benzoin-type 
transformation.
43
 Although this reaction benefits from the intramolecular setting, the observed 
efficiency (70%) indicates great reactivity of the catalyst, considering the steric bulk of the 
substrate.  This time we employed a full equivalent of the catalyst 118 in combination with 
enone 47 (1.0 equiv), aldehyde 48 (2.0 equiv) and Et3N (10 equiv) for the Stetter reaction.  After 
refluxing the mixture for 16h in CH2Cl2, the coupled product 115 was only isolated in 24% yield.  
In the course of the reaction, substantial amount of “rubber” material precipitated out of the 
solution, implying polymerization of enone 47.  
 34 
 
Figure 11. Utilize the Rovis catalyst for the Stetter reaction 
 
In the search for a proper catalyst for our coupling reaction, a thiazolium-based NHC 
catalyst 119 caught our attention (Scheme 18).  This catalyst exhibited great reactivity in a 
hydroacylation-Stetter cascade reaction disclosed by Glorius in 2010.
44
  The in situ-generated 
NHC catalyst derived from deprotonation of 119 activated aldehyde 120 to form the 
corresponding Breslow intermediate 121 that added to the tethered alkyne functionality.  The 
resulting enone product 122, under the influence of the same NHC catalyst, participated in a 
Stetter reaction with external aldehydes 123 to give 1,4-diketone products 124 in yields ranging 
from 65% to 90%.  Of great interest to us is the ability of incorporating unreactive aldehyde, 
such as isobutyraldehyde 123 (R= 
i
Pr) as the coupling partner.  In comparison to aromatic 
aldehydes, isobutyraldehyde is usually much less reactive due to greater steric hindrance.  
However, the comparably high yield obtained utilizing isobutyraldehyde encouraged us to 
explore the reactivity of 119 in our coupling reaction. 
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Scheme 18. Hydroacylation-Stetter cascade reaction 
 
 
Following Glorius’s protocol,45 we synthesized the thiazolium salt 119 to probe its 
reactivity in coupling 47 and 48 (Figure 12).  The catalyst precursor 119 (20 mol %) and K2CO3 
(40 mol %) were weighed in the glove box and added in the reaction vial equipped with aldehyde 
48 (1.0 equiv) and enone 47 (1.5 euqiv).  Anhydrous THF was introduced in the reaction mixture 
under N2 atmosphere.  This THF solution was refluxed for 3 h with exclusion of air to afford the 
coupled product 115 in quantitative yield with no observed benzoin condensation.  This 
unparalleled efficacy of 115 is rather difficult to analyze without thorough mechanistic studies.  
It is well known that the performance of an NHC catalyst not only relies on its σ-donating 
property and thus the nucleophilicity of the free NHC, but also on the π-donating character 
relevant to the nucleophilicity of the Breslow intermediate.
45
 Based on our results, a highly 
unsymmetrical environment of the carbene catalyst with bulky substitution (Mes) on the nitrogen 
atom and no substitution on the sulfur atom may be responsible for this particular reactivity.  
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Nevertheless, the great efficiency of our coupling reaction highlights the potential of utilizing the 
intermolecular Stetter reaction for complex molecule synthesis. 
 
 
Figure 12. Optimized conditions for the Stetter reaction 
 
2.5 BIS-SPIROKETAL SYNTHESIS 
The success of the coupling reaction propelled us to investigate the proposed biomimetic 
ketalization of acyclic 115 to construct the bis-spiroketal in spirolide C (Figure 13).  To simplify 
the synthesis, we planned to use acidic conditions to remove the silyl groups and also facilitate 
the cyclization.
46
  Treating 115 with camphorsulfonic acid (0.5 equiv) in MeOH provided the 
bis-spiroketals trans-125 and cis-125 in 72% yield after 16 h.  The diastereoselectivity was 6:1 
favoring the unnatural trans isomer which is parallel to the results observed in other groups.
12,13
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Attempts to shift the equilibrium towards the desired epimer proved unfruitful, including 
increasing reaction temperature which caused complete decomposition and switching to non-
polar solvent such as cyclohexane which shut down the ketalization due to lack of solubility.  We 
believe that the unnatural epimer trans-125 adopts a conformation that accommodates optimal 
hydrogen bonding interaction between free hydroxyl groups and the ether linkage in the tricycle.  
Nonetheless, the equilibration to the desired epimer is envisaged to occur when closing the 
macrocycle, since the natural epimer places the two “arms” of the bis-spiroketal in proximity 
which will become the future diene and dienophile components for the Diels-Alder reaction.  
 
 
Figure 13. Acid-mediated silyl group removal and concomitant cyclization 
 
In comparison to spirolide C, bis-spiroketals (trans-125 and cis-125) possessed a ketone 
instead of an exo methylene group at C24 (Eq 2).  A methylenation of this ketone unit was 
warranted to continue the synthesis of spirolide C.  Considering most methylenation conditions 
are not compatible with free hydroxyl groups, protecting the diol seemed necessary prior to the 
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olefination.  Surprisingly, treating 125 with TBSOTf and 2,6-lutidine at 0 °C led to complete 
decomposition within 1h (Eq 2).  We assumed the unanticipated complication was due to the 
inductive effect of the β-alkoxy group that increased the acidity of the α proton (H1) next to the 
ketone, resulting in the formation of a silyl enol ether.  This hypothesized silyl enol ether 
intermediate could lead to side products via ring opening the six-membered ring and/or 
nucleophilic addition to carbonyls in an intermolecular or intramolecular fashion.  In response, 
we needed to search for an appropriate olefination method to install the methylene in the 
presence of free hydroxyl groups and the acidic α proton. 
 
 
 
Methylenation of the sensitive and sterically hindered ketone 125 was achieved through a 
Takai olefination (Scheme 19).
47
 The active methylenation reagent 126 was generated by mixing 
CH2I2, Zn dust, and catalytic PbI2 in THF that was followed by addition of TiCl4.  The identity of 
the reagent was suggested as a germinal dizinc-Ti(II) complex 126.
48
 Exposing 125 to 126 
produced 127 in 58% yield after stirring at 0 °C for 3h.  The diastereomeric ratio was unchanged 
at this stage.  The subsequent TBS silylation of the diol 127 proceeded smoothly with TBSOTf 
and 2,6-lutidine, providing the protected bis-spiroketals (cis-45 and trans-45) in a combined 90% 
yield (Scheme 19).  Interestingly, the diastereomeric ratio changed from 1:6 to 1.5:1, favoring 
the desired epimer (cis-45).  It was assumed that by breaking the hydrogen bonding, the ground 
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state energy gap between these two epimers changed accordingly.  Further, these epimers were 
separable by flash column chromatography.  In order to enrich the desired epimer, the isolated 
trans-45 was equilibrated in MeOH with excess PPTS, affording a 1:1 ratio of cis-45 to trans-45 
after 1 h (Scheme 19).  Therefore, by one cycle of separation and re-equilibration, we can access 
cis-45 in a synthetically useful yield (60~70%).  
 
Scheme 19. Finalize the synthesis of bis-spiroketal cis-45 
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In conclusion, we completed the stereoselective synthesis of bis-spiroketal cis-45.  The 
route we developed highlighted the unprecedented implementation of an intermolecular Stetter 
reaction in fragment coupling.  The ensuing acid-facilitated desilylation and ketalization 
provided an efficient access to the bis-spiroketal structure which upon functional group 
manipulations delivered cis-45 with the desired configuration.  This convergent approach should 
also be appropriate for the synthesis of other members in the spirolide family, and amenable to 
the generation of a range of non-natural spiroketal analogs for further structure and biological 
studies.  
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3.0  INTRODUCTION 
The availability of efficient syntheses of enantioenriched α-hydroxy carbonyl compounds [(R)-
128 and (S)-128] is of great importance in the synthetic community due to their prevalence in 
many biologically active molecules.  Compounds possessing this unit are useful synthons for 
asymmetric synthesis of natural products, including antitumor agents, antibiotics, pheromones, 
and sugars.
49
  Many methods have been developed to prepare these compounds  [(R)-128 and 
(S)-128], among which the enantioselective oxidation of enolates has been used most frequently 
(Figure 14).  Variants of this method fall into two categories: using stoichiometric chiral 
inducing agents or employing asymmetric catalysis on the prochiral enolates.  The latter 
approach is more efficient and challenging and is the focus of the work in this document. 
 
 
Figure 14. Chiral α-hydroxy carbonyl compounds and enantioselective enolate oxidation methods 
 
N-Sulfonyl oxaziridine 130 has emerged as one of the most widely used electrophilic 
oxidants to allow for direct enolate oxidation (Scheme 20).
49
  Such reactivity lies in the weak N-
O bond as well as the strong electron withdrawing character of the sulfonyl group.  The 
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hydroxylation is thought to proceed through a nucleophilic attack of enolate carboanion 129 at 
the electrophilic oxygen atom in 130, generating the transient sulfonamide anion 131.  This 
intermediate will collapse and liberate the α-hydroxy carbonyl compound 133, along with N-
sulfonyl imine byproduct 132.
50
  Precedent of utilizing oxaziridine 130 to accomplish the 
enantioselective enolate α-hydroxylation will be discussed in the following chapter.   
 
Scheme 20. General mechanism of enolate oxidation with N-sulfonyl oxaziridine 
 
 
3.1 ASYMMETRIC ENOLATE ALPHA-HYDROXYLATION WITH 
STOICHIOMETRIC CHIRAL INDUCING AGENTS 
The conventional methods for asymmetric enolate α-hydroxylation with N-sulfonyl oxaziridines 
involve either stoichiometric chiral auxiliaries or chiral oxidizing reagents.  When using chiral 
auxiliaries, the stereo outcome is controlled by the covalently bonded chiral subunit which is 
removed after the oxidation.   
         Evans disclosed an asymmetric oxygenation of chiral imide enolates with racemic N-
benzenesulfonyl oxaziridine (±)-135 (Davis’ reagent).51  Treating the sodium enolate of 136 with 
a slight excess of (±)-135 gave (R)-137 and (S)-137 in a ratio from 90:10 to 99:1 (Table 2).  The 
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author also noticed a counter-ion dependent phenomenon in product distribution.  The sodium 
enolate of 136 gave predominately α-hydroxy products 137, while the lithium counterpart led to 
54% of 137 as well as 44% of the aldol adduct 138.  The carboximide auxiliary was removed 
without substantial racemization by transesterification using Mg(OMe)2 in MeOH at 0 °C.  In 
most cases, methanolysis proceeded in yields ranging from 80% to 90%.  However, the base-
catalyzed intramolecular acyl transfer became prevalent with the hindered substrates (R=iPr, tBu, 
etc) (Scheme 21).   
 
Table 2. Asymmetric α-hydroxylation of chiral carboximide enolates 
 
 
Scheme 21. Possible acyl transfer in the methanolysis step 
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Another example of auxiliary induced α-hydroxylation was demonstrated by Enders and 
Bhushan in the study of chiral hydrazones (Scheme 22).
52
 The azaenolate derived from (S)-
amino-2-(methoxymethyl)pyrrolidine hydrazone 139 was reacted with (±)-135, affording  the α-
hydroxy hydrazone 140.  The subsequent ozonolysis removed the auxiliary, providing the chiral 
hydroxyl ketone that was isolated after acylation in excellent enantioselectivity (93% ee).  
 
Scheme 22. Chiral hydrazone based enantioselective α-hydroxylation 
 
 
Despite that chiral auxiliary induced asymmetric enolate hydroxylation often provides 
high levels of enantioselectivities, an inherent disadvantage of any chiral auxiliary based 
asymmetric synthesis is the necessity for preparing and eventually removing the auxiliary.  This 
problem can be avoided by using chiral oxaziridines to accomplish stereocontrol.  The most 
frequently used chiral oxaziridines are camphorsulfonyl oxaziridine 143
53
 and its derivatives 
(such as 144).
54
 Yields and enantioselectivities highly depended upon the nature of the 
substrates, counterions of the enolates, the solvent, reaction temperature, and the chiral 
oxaziridines.  The influence of these variables, however, was often case-specific.
49
  Although 
great enantioselectivity could be achieved by careful choice of the chiral oxaziridine (Scheme 
23), in many cases, the stereo induction was only moderate. 
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Scheme 23. Chiral oxaziridine induced enantioselective α-hydroxylation 
 
 
3.2 CATALYTIC ASYMMETRIC ENOLATE ALPHA-HYDROXYLATION 
In comparison to auxiliary-controlled enantioselective enolate α-hydroxylation, methods based 
on asymmetric catalysis have significant advantages including atom economy and limited 
functional group manipulations (such as removal of the auxiliary).  The indirect catalytic 
approach has been disclosed for over two decades, including the asymmetric dihydroxylation of 
enol ethers developed by Sharpless,
55
 the asymmetric epoxidation of silyl enol ethers with a 
chiral dioxirane,
56
 and the asymmetric epoxidation of enol ethers with a chiral Mn-salen 
catalyst.
57
 One common feature of these methods is that they all require converting the carbonyl 
substrates to isolable enol ethers prior to the oxidation step.  As a result, the enantioselectivity of 
the reaction depends on the Z,E purity of the prochiral enol ether and exclusive Z or E enol ether 
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formation is not usually trivial.  Therefore, this type of methods has not received wide 
applications in organic synthesis.  
The development of direct α-oxygenation of carbonyl compounds in a catalytic, 
asymmetric fashion has not been accomplished until very recently.
58
  MacMillan
58b
 and Zhong
58a
 
simultaneously developed enantioselective α-oxygenation of aldehydes utilizing proline as the 
organocatalyst and nitrosobenzene 148 as the oxidant (Eq 3).  Oxidation of the aldehyde was 
facile at ambient temperature, providing excellent enantioselectivity (94% ee to 99% ee).  The α-
oxyaldehyde products were oligomeric in solution and thus were isolated after being reduced to 
the corresponding primary alcohols 149. 
 
 
 
Shortly after, Hayashi and co-workers reported an analogous proline-catalyzed 
enantioselective α-oxygenation of ketones.58f As illustrated in Scheme 24, reacting 
cyclohexanone 150 with nitrosobenzene 148 catalyzed by proline (10 mol%) in DMF gave the α-
aminoxy compound 152 (77% yield, >99% ee) after 24h.  Hydrogen bonding between the 
carboxylic acid group of proline and the nitrogen atom of nitrosobenzene was critical for 
enantioselctivity by securing a closed transition state 151.  The N-O bond cleavage was 
accomplished by exposing 152 to CuSO4 (0.3 equiv) in MeOH to deliver the chiral α-hydroxy 
compound 153 with negligible epimerization (97% ee).  This methodology, however, only 
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applies to simple cyclic ketone substrates.  When using acyclic ketones, reaction produced a 
mixture of α-oxygenated and aminated products. 
 
Scheme 24. Proline catalyzed α-oxygenation of cyclic ketones 
 
 
Despite the progress in relevant organocatalysis, chiral auxiliary assisted enolate α-
hydroxylation still remains the method of choice when preparing optically active α-hydroxy 
carbonyl compounds due to broader substrate scope and better reaction consistency.  An 
asymmetric catalysis that embraces wide substrate scope and operational simplicity has not been 
discovered.  Such an unmet challenge prompted us to explore the prospect of utilizing the 
ketene-oxaziridine cyclocondensation as a surrogate to accomplish the enantioselective enolate 
α-hydroxylation. 
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4.0    DEVELOPMENT OF CATALYTIC ASYMMETRIC ENOLATE ALPHA-
HYDROXYLATION VIA ACID CHLORIDE-OXAZIRIDINE CYCLOCONDENSATION 
4.1 REACTION DESIGN 
Our goal was to develop a catalytic asymmetric methodology to prepare enantioenriched α-
hydroxy carbonyl compounds with broad substrate scope using easily accessible catalysts.  
Encouraged by the success of cinchona alkaloid catalyzed ketene aldehyde cyclocondensation 
developed in our group,
21
 we were interested in investigating the potential of the ketene-
oxaziridine cyclocondensation as a surrogate for enolate α-hydroxylation methodologies (Figure 
15).  Specifically, the cyclocondensation of the in situ-generated ketene and racemic N-sulfonyl 
oxaziridines (±)-130 would gave enantioenriched oxazolidinone heterocycles, [(S)-155 or (R)-
155] which upon ring opening with nucleophiles, generate an array of chiral α-hydroxy carbonyl 
compounds [(S)-156 or (R)-156]. 
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Figure 15. Catalytic synthesis of chiral oxazolidinones as the surrogate for enolate α-hydroxylation 
 
Our reaction design was guided by previous studies in our laboratory which determined 
that chiral ketene enolates, generated by addition of cinchona alkaloids (TMSQn or TMSQd) to 
ketenes, exerted excellent facial selectivity and reactivity toward electrophiles such as aldehydes 
and imines.
21,59
  Considering N-sulfonyl oxaziridines were highly electrophilic, we attempted to 
investigate their reactivity towards the chiral ketene-derived enolates.  Precedent has shown that 
the reaction of metal enolates and N-sulfonyl oxaziridines directly led to α-hydroxyl carbonyl 
compounds (Scheme 25).  However, Evans noticed that the formation of α-hydroxy carbonyl 
compounds (133) and the imine byproduct (158) was not a concerted process, suggesting a 
stepwise mechanism where a short-lived sulfonamide intermediate 159 was involved in the 
reaction.
51
 This sulfonamide intermediate is the key to our proposed catalytic ketene-oxaziridine 
cyclocondensation described in Scheme 26.  When the ketene enolate 161 underwent 
nucleophilic attack at oxaziridine (±)-130, sulfonamide intermediate 162 thus generated would 
cyclize onto the carbonyl to give enantioenriched oxazolidinone 163 along with regeneration of 
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the catalyst 157.  Oxazolidinones 163 could be converted to α-hydroxy carbonyl compounds 
through nucleophilic ring openings. 
 
Scheme 25. Evans’ mechanistic study in the metal enolate-oxaziridine reaction 
 
 
Scheme 26. Proposed mechanism of the ketene-oxaziridine cyclocondensation 
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4.2 PROOF-OF-CONCEPT EXPERIMENTS 
The proof-of-concept experiment was carried out using propionyl chloride as the ketene 
precursor, racemic N-benzenesulfonyl oxaziridine (±)-135 as the oxidant, and TMSQd as the 
catalyst.  The role of the Lewis acid (LiClO4), similar as in the AAC chemistry, was believed to 
activate the oxaziridine by coordination to its oxygen atom.  Following the typical AAC 
protocol,
21
 slow adding propionyl chloride (2.0 equiv) into a −78 °C solution of oxaziridine (±)-
135 (1.0 equiv), diisopropylethylamine (2.0 equiv), TMSQd (20 mol %) and LiClO4 (1.0 equiv) 
gave oxazolidinones 166a and 166b as a 3:1 inseparable mixture of diastereomers (43%) [See 
the experimental section (Chapter 6.0) for the relative stereochemistry assignments of 
oxazolidinone products].  The slow addition was performed via a syringe pump to avoid 
substantial ketene dimerization.
60
 Oxaziridine (±)-135 was consumed completely at the end of 
the acid chloride addition.  The reaction mixture was then quenched by addition of excess diethyl 
ether at −78 °C and warmed to ambient temperature followed by filtration through a silica gel 
plug.  Besides the desired product (166a and 166b), a substantial amount of N-sulfonyl imine 
158 and benzaldehyde derived from hydrolysis of 158 were also obtained.  Imine 158 co-eluted 
with the oxazolidinones, therefore, hydrolysis of the imine using 5% HCl in MeOH was 
necessary prior to flash column chromatography.  As anticipated, the enantioselectivities of both 
diastereomers were excellent (>98% ee).  The lack of diastereoselectivity of this reaction was 
inconsequential, as the aminal stereocenter would be removed in the ring-opening reaction. 
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Figure 16. Proof-of-concept experiment for the ketene-oxaziridine cyclocondensation 
 
4.3 PROBING THE EFFECTS OF LEWIS ACIDS ON THE 
CYCLOCONDENSATION 
Encouraged by the success of the proof-of-concept experiment, we set out to optimize the 
reaction conditions to improve the yields.  Since the Lewis acid would increase the 
electrophilicity of the oxaziridine by binding to the oxygen atom, the reaction optimization was 
initiated with a Lewis acid screen.  The choice of Lewis acids was strictly limited, as the catalyst 
(TMSQn or TMSQd) we employed in the cyclocondensation is a Lewis base and will potentially 
form irreversible complexes with strong Lewis acids.  We eliminated strong Lewis acids such as 
TiCl4 and BF3·OEt2 and focused on oxophilic Lewis acids with moderate strength (Table 3).  
Reactions were performed by employing TMSQd as the catalyst (20 mol %), oxaziridine (±)-135 
(1.0 equiv) and two fold excess of methyl ketene which was generated in situ from propionyl 
chloride at −78 °C.  Except in the cases using boron-based Lewis acids (Entries 8 and 9), small 
amounts of ether were utilized to assist solvating the Lewis acids.  The diastereoselectivity was a 
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consistent 1:1 except when using LiClO4 (Entry 1).  Lewis acids such as MgCl2, MgBr2·Et2O, 
Sc(OTf)3, In(OTf)3 and B(OPh)3 (Entries 2, 3, 6, 7, and 8) showed no advantages over LiClO4 in 
terms of yields.  ZnCl2 and Zn(OTf)2 (Entries 4 and 5) increased the yield by about 10%.  The 
best yield (70%) was attained when utilizing catalytic B(OMe)3 (Entry 9). 
 
Table 3. Investigation into the Lewis acids to promote the acid chloride-oxaziridine cyclocondensation 
 
 
With B(OMe)3 deemed as the appropriate Lewis acid, we were eager to test the reaction 
against other ketene substrates.  Unfortunately, we observed a drastic decrease in yields as the 
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steric bulk of the ketene increased.  For example, reactions employing pentanoyl chloride 154g 
and phenylacetyl chloride 154a provided the corresponding oxazolidinones in 54% and 24% 
yields respectively (Figure 17).  Oxaziridine (±)-135 was not completely consumed at the end of 
the reactions while full consumption was observed after 2h when using methyl ketene.  
Prolonging the reaction time, however, did not increase the reaction conversion, implying that 
the catalyst turnover was shut down after certain time.   
 
 
Figure 17. Cyclocondensations incorporating ketenes other than methyl ketene 
 
4.4 COMPETING SIDE REACTIONS 
As mentioned above, we noticed that the catalyst (TMSQn or TMSQd) was deactivated after 
certain time in the phenylacetyl chloride-oxaziridine cyclocondensation.  We assumed the 
catalyst was consumed or sequestered by competing side reactions.  One plausible assumption 
was oxidation of the catalyst by the oxaziridine, based on the precedent that N-sulfonyl 
oxaziridines (±)-135 could rapidly oxidize quinine 168 at ambient temperature to afford the 
corresponding N-oxide 169 (Eq 4).
61
  In order to probe the extend of this oxidation in our 
reaction system, we performed a control experiment utilizing oxaziridine (±)-135 (1.0 equiv), 
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TMSQn (20 mol %) and CD2Cl2 as the solvent (Eq 5).  After 3.5h at −78 °C, excess 
triethylamine was added to quench the unreacted oxaziridine.  Crude 
1
H NMR of this reaction 
mixture showed 44% consumption of TMSQn, confirming that even at −78 °C, the oxaziridine 
could oxidize the catalyst to the N-oxide.  This N-oxide was, however, inactive to catalyze the 
cyclization due to lack of electron lone pair on the quinuclidine nitrogen atom.  Further, the 
byproduct of this unproductive oxidation was N-sulfonyl imine 158 that could undergo 
cyclocondensation with the ketene under the influence of the same catalyst to give β-lactam 170 
(Eq 6).  This reaction path was confirmed by X-ray crystal structure of 171 isolated as a 
byproduct when reacting propionyl chloride with N-p-nosyl oxaziridine.  In conclusion, when the 
cyclocondensation between the ketene and the oxaziridine was slow, the oxaziridine would 
deactivate the catalyst through N-oxidation and thus terminate the catalytic cycle.  Therefore, we 
needed to find an oxaziridine that could react more rapidly with the ketene than with the catalyst.   
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4.5 N-P-NOSYL OXAZIRIDINE AS THE NEW OXIDANT 
In order to make the desired cyclocondensation more facile than the competing side reactions, 
we shifted our focus to using the more electrophilic oxaziridine, racemic N-p-nosyl oxaziridine 
(±)-172.
62
  Due to the strong electron-withdrawing nature of the nitro group, (±)-172 is much 
more reactive than the parent Davis’ reagent.  Indeed, in the reaction with phenylacetyl chloride, 
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full consumption of (±)-172 was observed after 2h at −78 °C.  However, only about 80% of 
oxaziridine (±)-172 was transformed to oxazolidinones 173a (Table 4), indicating the competing 
side reactions were not completely suppressed.  It is noteworthy that the reaction proceeded with 
equal efficiency in the absence of the Lewis acid (Entry 1).  For the operational convenience, the 
following investigations were conducted without incorporating Lewis acids. 
 
Table 4. Investigation into the reactivity of N-p-nosyl oxaziridine in the acid chloride-oxaziridine 
cyclocondensation 
 
 
The more electrophilic oxaziridine (±)-172 did not require Lewis acid activation for the 
ketene-oxaziridine cyclocondensation, however, the selectivity of (±)-172 needed to be further 
improved.  Despite its full consumption in the reaction with phenyl acetyl chloride, we only 
isolated 61% yield of the corresponding oxazolidinone products (Scheme 27).  The byproducts of 
this particular cyclocondensation were unfortunately unidentifiable.  However, analogous 
reactions utilizing propionyl chloride as the ketene precursor led to cis and trans β-lactams (171 
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and 176) besides the desired oxazolidinones.  As mentioned before, the N-sulfonyl imine 175 
that led to the β-lactam formation was arising from N-oxidation of the catalyst by the oxaziridine.  
Therefore, if we could limit the exposure of oxaziridine (±)-172 to the catalyst prior to the 
cyclocondensation, we could potentially suppress the β-lactam formation and increase the yield 
of oxazolidinones.  To this end, we devised the reaction protocol by slow adding oxaziridine (±)-
172 into the reaction.  This was achieved by adding a mixture of 154a and (±)-172 into a −78 °C 
solution of TMSQn and 
i
Pr2NEt over a course of 2 h.  As a result, the yield of 173a was 
increased to 79% (Scheme 27).   
 
Scheme 27. Revised protocol for the acid chloride-oxaziridine cyclocondensation 
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4.6 SUBSTRATE SCOPE OF THE ACID CHLORIDE-OXAZIRIDINE 
CYCLOCONDENSATION 
Having formulated the optimized conditions for the acid chloride-oxaziridine cyclocondensation, 
we decided to probe the reaction scope with an array of structurally diverse ketenes.  Slow 
adding the mixture of (±)-172 (1.0 equiv) and 154a-n (1.0 equiv) into a CH2Cl2 solution of 
TMSQn (20 mol %) and 
i
Pr2NEt (2.0 equiv) at −78 °C over the course of 2h gave oxazolidinones 
173a-n in good yields (59~82%) and excellent enantioselectivities (> 98% ee) (Table 5).  Acid 
chlorides producing straight chain and β-branched alkyl ketenes provided the corresponding 
oxazolidinone in great yield (71~75%) and excellent enantioselectivity (>98% ee) (Entries e-h).  
Aryl-substituted acid chlorides participated in the cyclocondensation to produce the 
oxazolidinones with equal enantioselectivity (>98% ee) despite the greater tendency to 
epimerization (Entries a-d).  In addition, acid chlorides possessing various heterocyclic or 
common heteroatom functionalities also participated in efficient condensation with (±)-172 
(Entries j, k, and m).  Acid chlorides producing -branched alkyl ketenes, however, afforded 
varied yields depending on the bulk of the ketene (Entries i and n).  For example, 
cyclopropylacetyl chloride 154i provided oxazolidinones in comparable yield (70%), while 
cyclohexylacetyl chloride 154n only delivered a modest yield (29%).  The steric hindrance of the 
cyclohexane ring presumably impeded the cyclocondensation to the degree that the competing 
side reactions became dominant.   
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Table 5. Investigation into the substrate scope of the acid chloride-oxaziridine cyclocondensation 
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4.7 ACCESS TO ENANTIOENRICHED ALPHA-HYDROXY CARBONYL 
COMPOUNDS 
The enantioenriched oxazolidinones provided an access to various -hydroxy carbonyl 
compounds through facile ring openings achieved using diverse nucleophiles.  Reacting the 1:1 
diastereomeric mixture of 5-phenyl oxazolidinone 173a (> 98% ee) with catalytic NaOMe (0.1 
equiv) in MeOH afforded (S)-methyl mandelate 177 with limited epimerization (80%, 93% ee) 
(Entry 1).  Attempts to use neutral conditions utilizing substoichiometric amount of DMAP in 
MeOH was unsuccessful, resulting in greater epimerization and lower yields.  Likewise, reacting 
173a with ethyl thiolate (EtSK) in THF at 0 °C provided the α-hydroxy thioester 178 with no 
erosion in enantiomeric purity (72%, >98% ee) (Entry 2).  Amine-mediated ring opening, 
exemplified by NH3, proceeded smoothly in the ammonia saturated methanol solution to afford 
the α-hydroxy amide 179 (83%, >98% ee) (Entry 3).  Attempts at ring opening the oxazolidinone 
with morpholine catalyzed by DMAP resulted in a great yield (90%) of the amide product 180, 
however, it was accompanied by significant epimerization (Entry 4).  Under neutral conditions 
(amine or alcohol coupled with catalytic DMAP), the ring opening reaction proceeded very slow 
and usually required overnight time to complete, leading to a greater degree of epimerization.  
Thus, to access enantioenriched α-hydroxy carbonyl compounds, careful choice of nucleophile is 
warranted and anion-based nucleophiles tend to shorten the reaction time and reduce the 
epimerization.   
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Table 6. Ring openings of oxazolidinones 
 
 
In conclusion, cinchona alkaloid catalyzed ketene-oxaziridine cyclocondensations 
provide a catalytic asymmetric alternative to tranditional enolate α-oxidation reactions.  Using 
readily obtained acid chloride ketene precursors and an easily prepared oxaziridine oxidant, 
highly enantioenriched oxazolidinones are prepared in good yields that afford access to a wide 
variety of chiral α-hydroxy carbonyl compounds. 
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5.0  EXPERIMENTAL FOR SPIROLIDE C SYNTHESIS 
General Information: Unless otherwise indicated, all reactions were performed in dry 
glassware under an atmosphere of oxygen-free nitrogen using standard inert atmosphere 
techniques for the manipulation of both solvents and reagents.  Anhydrous solvents were 
obtained by passage through successive alumina- and Q5-packed columns on a solvent 
purification system.  2,6-Lutidine, N,N-diisopropylethylamine were purified by distillation over 
CaH2. (2S,6S)-4-Benzyl-1,7-bis(trifluoromethylsulfonyl)-2,6-diisopropyl-1,4,7-triazaheptane 186 
was prepared according to the literature procedure.
63
  3-Mesityl-5,6,7,8-tetrahydro-4H-
cyclohepta[d]thiazol-3-ium perchlorate 119 was synthesized by following Glorius’ procedure.45  
Commercially available acetyl bromide was distilled under nitrogen.  NMR spectra were 
recorded at the indicated magnetic field strengths with chemical shifts reported relative to 
residual CHCl3 (7.27 ppm) for 
1
H and CDCl3 (77.0 ppm) for 
13
C spectra.  Analytical thin layer 
chromatography (TLC) was performed on 0.25 mm silica gel 60-F plates.  Flash chromatography 
was performed over silica gel (230-240 mesh).  Analytical gas chromatography (GC) was 
performed using a flame ionization detector and split mode capillary injection system using 
Varian Chirasil-Dex CB WCOT fused silica 25 m x 0.25 mm column (CP 7502).  The 
concentration of the solution for optical rotations was in the unit of g 100 mL
-1
.   
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 (S)-4-(3-Methylbut-3-en-1-yl)oxetan-2-one (49): To a stirred solution of (2S,6S)-4-benzyl-1,7-
bis(trifluoromethylsulfonyl)-2,6-diisopropyl-1,4,7-triazaheptane 186 (1.6 mmol, 0.1 equiv) in 
110 mL of CH2Cl2 at 0 °C was added Me2AlCl (1.6 mL, 1.0 M solution in hexane).  This 
homogeneous solution was removed from the ice bath and stirred at ambient temperature for 1h 
before being cooled to −50 °C.  To this −50 °C solution was added 4.74 mL of N,N-
diisopropylethylamine (27.2 mmol, 1.7 equiv) followed by dropwise addition of 2.25 mL of 
acetyl bromide (30.4 mmol, 1.9 equiv) over a period of 60 s.  The resulting yellow solution was 
stirred for 120 s whereupon a solution of 1.58 g of aldehyde 50
64
 (16.0 mmol, 1.0 equiv) in 5 mL 
of CH2Cl2 was added dropwise.  The reaction was stirred at −50 °C for 16 h.  Saturated aqueous 
NH4Cl (100 mL) was added and mixture was extracted with CH2Cl2 (3 x 50 mL).  The combined 
organic extracts were dried over Na2SO4, filtered and concentrated.  The resulting crude residue 
was purified by flash chromatography on silica gel (15% Et2O in hexanes) to afford 2.04 g (91%) 
of the title compound as a clear oil.      
   −0.91 (c, 1.6, CHCl3); IR (thin film): 1827, 1134, 
1113, 888, 831 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 4.78 (s, 1H), 4.72 (s, 1H), 4.55-4.50 (m, 
1H), 3.52 (dd, J= 16.5, 6.0 Hz, 1H), 3.09 (dd, J= 16.5, 4.0 Hz, 1H), 2.20-2.08 (m, 2H), 2.05-1.98 
(m, 1H), 1.94-1.87 (m, 1H), 1.75 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 168.2, 143.6, 111.1, 
70.8, 42.8, 32.9, 32.6, 22.3; HRMS (ES+) m/z calcd for C8H13O2 [(M+H)
+
]: 141.0916; found: 
141.0926. 
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 (S)-3-(tert-Butyldimethylsilyloxy)-N-methoxy-N,6-dimethylhept-6-
enamide (57): To a suspension of 1.52 g of N,O-
dimethylhydroxylamine hydrochloride (15.6 mmol, 2.0 equiv) in 18 mL of CH2Cl2 at 0 °C was 
slowly added 15.6 mL of dimethylaluminum chloride (15.6 mmol, 2.0 equiv, 1M hexanes 
solution).  Once the addition was complete, the reaction was removed from the ice bath and 
stirred at ambient temperature for 1h.  The reaction was cooled to −30 °C and a solution of 1.09 
g (7.80 mmol, 1.0 equiv) of β-lactone 49 in 4 mL of CH2Cl2 was added over the course of 30 min 
via a syringe pump.  The reaction was stirred for additional 45 min at this temperature and 
quenched with 40 mL of saturated Rochelle’s salts solution (Caution: gas evolution).  The 
mixture was then warmed to ambient temperature and stirred until two homogenous phases 
resulted.  The organic layer was separated and the aqueous phase was extracted with Et2O (3 x 
40 mL).  The combined organic extracts were washed with brine, dried over MgSO4, filtered and 
concentrated.  The crude material was used without further purification. 
              To a stirred solution of crude product obtained above in 25 mL of CH2Cl2 at −50 °C was 
added 1.4 mL of 2,6-lutidine (12 mmol, 1.5 equiv) followed by 2.1 mL of TBSOTf (9.4 mmol, 
1.2 equiv) dropwise.  The reaction was stirred at this temperature for 1h and then quenched by 30 
mL of saturated NaHCO3 aqueous solution.  The mixture was warmed to ambient temperature 
and extracted with CH2Cl2 (3 x 20 mL).  The combined organic extracts were dried over Na2SO4, 
filtered and concentrated.  The crude material was purified via flash chromatography on silica 
gel (10% EtOAc in hexanes) to afford 2.31 g (94% over two steps) of the titled compound as a 
clear oil.      
  +1.6 (c 2.3, CHCl3); IR (thin film): 2954, 2932, 2857, 1740, 1666, 1463, 1443, 
1385, 1254, 1178, 1090, 1033, 1004, 886, 836, 812, 776 cm
-1
; 
1
H NMR (400 MHz, CDCl3): δ 
4.703-4.701 (m, 1H), 4.689-4.688 (m, 1H), 4.29-4.23 (m, 1H), 3.70 (s, 1H), 3.18 (s, 1H), 2.75 
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(dd, J= 14.4, 7.2 Hz, 1H), 2.42 (dd, J= 14.4, 5.2 Hz, 1H), 2.15-2.01 (m, 2H), 1.73 (s, 3H), 1.72-
1.57 (m, 2H), 0.88 (s, 9H), 0.08 (s, 3H), 0.04 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 172.4, 
145.8, 109.8, 69.2, 61.3, 39.5, 35.9, 33.2, 32.0, 25.9, 22.6, 18.1, -4.6, -4.7; HRMS (ES+) m/z 
calcd for C16H33NO3SiNa [(M + Na)
+
]: 338.2127; found: 338.2137. 
 
 
 
(S)-Methyl 7-(tert-butyldimethylsilyloxy)-10-methyl-5-oxoundec-10-enoate (62): To a stirred 
solution of 6.23 g of alkyl bromide (59)
25
 (24.8 mmol, 1.0 equiv) in 80 mL of Et2O at −78 °C 
was added 29.0 mL of 
t
BuLi (49.6 mmol, 2.0 equiv, 1.7 M solution in pentane) slowly.  The 
resulting solution was stirred at this temperature for 1.5 h, whereupon 4.70 g of Weinreb amide 
57 (15.0 mmol, 0.6 equiv) in 6 mL of Et2O was added over 40 min via a syringe pump.  The 
reaction was stirred at −78°C for additional 3 h.  The reaction was quenched by 70 mL of 
saturated NH4Cl aqueous solution and the mixture was warmed to ambient temperature.  The 
organic phase was separated and the aqueous phase was extracted with EtOAc (3 X 50 mL).  The 
combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated.  
The crude material was used without further purification. 
              To a stirred solution of the crude product obtained above in 70 mL of MeOH at ambient 
temperature was added 2.2 mL of H2O followed by 0.377 g of pyridinium p-toluenesulfonate 
(1.50 mmol, 0.1 equiv to the Weinreb amide) in one portion.  The reaction was stirred for 1h and 
cooled to 0 °C whereupon 9.98 g of Cs2CO3 (30.0 mmol, 2 equiv) was added in one portion.  The 
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reaction was stirred at 0 °C for 2h and then filtered through a plug of silica gel, eluting with 20% 
of EtOAc in hexanes.  The filtrate was concentrated under vacuum and the residue obtained was 
further purified via flash column chromatography on silica gel (2 L of 7% EtOAc in hexanes 
followed by 1 L of 15% EtOAc in hexanes) to afford 4.13 g (85% over 3 steps) of titled 
compound 62 as a clear oil, along with 0.42 g of unreacted Weinreb amide 57 recovered.  
    
  +1.9 (c 1.3, CHCl3); IR (thin film): 2953, 2932, 2857, 1741, 1716, 1439, 1374, 1254, 1196, 
1089, 1041, 837, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 4.67 (d, J= 16.5 Hz, 1H), 4.17 (pent, 
J= 5.5 Hz, 1H), 3.65 (s, 3H), 2.59 (dd, J= 15.0, 7.0 Hz, 1H), 2.49 (dt, J= 7.0, 4.5 Hz, 2H), 2.44 
(dd, J= 15.0, 5.0 Hz, 1H), 2.33 (t, J= 7.0 Hz, 2H), 2.01 (t, J= 7.5 Hz, 2H), 1.91-1.82 (m, 2H), 
1.70 (s, 3H), 1.62-1.52 (m, 2H), 0.85 (s, 9H), 0.05 (s, 3H), 0.00 (s, 3H); 
13
C NMR (125 MHz, 
CDCl3): δ 208.9, 173.6, 145.5, 109.9, 68.7, 51.5, 49.9, 43.4, 35.7, 33.1, 33.0, 25.8, 22.6, 18.6, 
18.0, -4.6, -4.7; HRMS (ES+) m/z calcd for C19H36O4SiNa [(M + Na)
+
]: 379.2281; found: 
379.2280. 
 
 
 
 (7S,10R)-Methyl-7-(tert-butyldimethylsilyloxy)-10,11-
dihydroxy-10-methyl-5 oxoundecanoate (65): 1.4 g of 
commercially available AD-mix-β was dissolved in 5 mL of H2O and 5 mL of 
t
BuOH.  The 
heterogeneous mixture was stirred at ambient temperature and produced two clear phases with 
the bottom phase appearing bright yellow.  The mixture was cooled to 0 °C and 0.34 g of olefin 
62 (1.0 mmol) dissolved in minimum amount of 
t
BuOH was added dropwise.  The mixture was 
stirred vigorously at 0 °C for 16h.  The reaction was quenched with 2 g of solid Na2SO3 and the 
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mixture was warmed to ambient temperature and stirred for 0.5 h.  The mixture was extracted 
with EtOAc (3 X 10 mL).  The combined organic extracts were washed with brine, dried over 
MgSO4, filtered and concentrated.  The crude material was purified via flash column 
chromatography on silica gel (150 mL of 50% EtOAc in hexanes then 250 mL of 100% EtOAc) 
to afford 0.35 g of titled compound 65 (95%) as a clear oil, along with 30 mg of unreacted olefin 
62.      
  +1.2 (c 1.1, CHCl3); IR (thin film): 3409, 2954, 2932, 2857, 1738, 1716, 1462, 1439, 
1409, 1375, 1254, 1203, 1175, 1050, 836, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 4.21 (pent, 
J= 5.0 Hz, 1H), 3.67 (s, 3H), 3.42 (t, J= 5.0 Hz, 2H), 2.62 (dd, J= 15.5, 6.5 Hz, 1H), 2.54-2.47 
(m, 4H), 2.34 (t, J= 7.0 Hz, 2H), 2.21 (t, J= 6.0 Hz, 1H), 1.92-1.83 (m, 2H), 1.64-1.46 (m, 4H), 
1.14 (s, 3H), 0.86 (s, 9H), 0.08 (s, 3H), 0.03 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 209.0, 
173.7, 72.4, 70.0, 68.9, 51.6, 49.4, 43.3, 33.2, 33.0, 31.0, 25.8, 23.2, 18.6, 18.0, -4.6, -4.8; 
HRMS (ES+) m/z calcd for C19H38O6SiNa [(M + Na)
+
]: 413.2335; found 413.2327. 
 
 
 
 (7S,10R)-Methyl-7-(tert-butyldimethylsilyloxy)-10-methyl-
5,11-dioxo-10 [(trimethylsilyl)oxy]undecanoate (66): A 
stirred biphasic mixture of diol 65 (1.68 g, 4.30 mmol, 1.0 
equiv) and KBr (0.512 g, 4.30 mmol, 1.0 equiv) in 40 mL of CH2Cl2 and 20 mL of saturated 
NaHCO3 aqueous solution was cooled to 0 °C.  A few crystals of 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO) were added in the reaction whereupon 5.8 mL of bleach (about 6% of 
NaOCl in H2O) was added portionwise.  The reaction turned orangey red and the color faded in 
0.5 h.  Another 0.7 mL of bleach was added and the reaction was stirred for additional 0.5 h.  
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The reaction was then quenched with 20 mL of saturated Na2S2O3 aqueous solution.  After 
separating the organic phase, the aqueous phase was extracted with CH2Cl2 (2 X 40 mL).  The 
combined organic extracts were dried over Na2SO4, filtered and concentrated.  The crude product 
was used without further purification. 
              To a stirred solution of aldehyde obtained above in 22 mL of CH2Cl2 at −78 °C was 
added 0.9 mL of 2,6-lutidine (7.7 mmol, 1.8 equiv) followed by 1.2 mL of TMSOTf (6.4 mmol, 
1.5 equiv) dropwise.  The reaction was stirred at this temperature for 1h and quenched by adding 
20 mL of saturated NaHCO3 aqueous solution.  The mixture was warmed to ambient temperature 
and extracted with CH2Cl2 (2 x 20 mL).  The combined organic extracts were dried over Na2SO4, 
filtered and concentrated.  The crude material was purified via flash column chromatography on 
silica gel (1 L of 14% EtOAc in hexanes) to afford 1.78 g of the titled compound 66 (90% over 2 
steps) as a clear oil.      
  +3.42 (c 3.19, CHCl3); IR (thin film): 2955, 2896, 2857, 1740, 1438, 
1410, 1375, 1253, 1196, 1142, 1082, 1021, 840, 777 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 9.52 (s, 
1H), 4.18-4.13 (m, 1H), 3.66 (s, 3H), 2.58 (dd, J= 15.5, 7.5 Hz, 1H), 2.49 (dt, J= 7.0, 3.0 Hz, 
2H), 2.38 (dd, J= 15.5, 5.0 Hz, 1H), 2.33 (t, J= 7.0 Hz, 2H), 1.92-1.82 (m, 2H), 1.67-1.61 (m, 
1H), 1.56-1.48 (m, 2H), 1.44-1.37 (m, 1H), 1.27 (s, 3H), 0.85 (s, 9H), 0.15 (s, 9H), 0.021(d, J= 
26.5 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) δ 208.7, 204.6, 173.6, 80.4, 68.7, 51.6, 49.7, 43.4, 
34.0, 33.0, 31.0, 25.8, 22.8, 18.6, 18.0, 2.3, -4.6, -4.8; HRMS (ES+) m/z calcd for C22H44O6Si2Na 
[(M + Na)
+
]: 483.2574; found: 483.2577. 
 
 
 (7S,10R)-Methyl-7-(tert-butyldimethylsilyloxy)-11-
hydroxy-10-methyl-5-oxo-10 (trimethylsilyloxy)tridec-12-
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enoate : To a stirred solution of 1.73 g of aldehyde 66 (3.80 mmol, 1.0 equiv) in 40 mL of THF 
at −78°C was added 10.0 mL of vinylmagnesium bromide (7.22 mmol, 1.9 equiv, 0.74 M 
solution in THF) dropwise.  The reaction was stirred at this temperature for 1.5h.  The reaction 
was then quenched by slow addition of 0.5 mL of glacial acetic acid followed by 40 mL of 
saturated NH4Cl aqueous solution.  The mixture was warmed to ambient temperature and the 
organic phase was separated.  The aqueous phase was extracted with EtOAc (3 X 30 mL) and the 
combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated.  
The material was purified via flash column chromatography on silica gel (200 mL of 15% 
EtOAc in hexanes then 600 mL 20% EtOAc in hexanes) to afford 1.48 g of the titled compound 
(80%) in a form of inconsequential diastereomers.  
1
H NMR (500 MHz, CDCl3): δ 5.84 (ddd, J= 
17.5, 10.5, 6.5 Hz, 1H), 5.31 (dt, J= 17.0, 1.5 Hz, 1H), 5.19 (dt, J= 10.5, 1.5 Hz, 1H), 4.16-4.10 
(m, 1H), 3.87-3.84 (m, 1H), 3.67 (s, 3H), 2.61-2.56 (m, 2H), 2.51 (dt, J= 7.5, 5.0 Hz, 2H), 2.41 
(dd, J= 15.0, 4.5 Hz, 1H), 2.34 (t, J= 7.5 Hz, 2H), 1.91-1.84 (m, 2H), 1.63-1.42 (m, 4H), 1.33 
(dt, J= 13.0, 4.0 Hz, 1H), 1.22 (s, 3H), 0.86 (s, 9H), 0.15 (s, 9H), 0.06 (s, 3H), 0.00 (s, 3H); 
13
C 
NMR (125 MHz, CDCl3): δ 209.1, 173.6, 136.4, 117.0, 79.4, 78.4, 69.3, 51.6, 49.9, 43.5, 33.0, 
31.4, 25.8, 23.8, 18.6, 18.0, 2.7, 2.5, -4.5, -4.8. 
 
 
 
 (7S,10R)-Methyl-7-(tert-butyldimethylsilyloxy)-10-
methyl-5,11-dioxo-10 (trimethylsilyloxy)tridec-12-enoate 
(47): To a stirred solution of 0.276 g of the allylic alcohol (0.565 mmol, 1.0 equiv) in 6 mL of 
CH2Cl2 at ambient temperature was added 0.360 g of Dess-Martin periodinane (0.850 mmol, 1.5 
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equiv) in one portion.  The resulting heterogeneous mixture was stirred for 1.5 h and quenched 
by 20 mL of 1:1 mixture of saturated NaHCO3 aqueous solution and saturated NaS2O3 aqueous 
solution.  The mixture was extracted with CH2Cl2 (3 X 20 mL) and combined organic extracts 
were dried over Na2SO4, filtered and concentrated.  The crude material was purified via flash 
column chromatography on silica gel (100 mL of 7% EtOAc in hexanes then 300 mL 15% 
EtOAc in hexanes) to afford 0.197 g of titled compound 47 (71%) as a clear oil.      
  +3.90 (c 
2.36, CHCl3); IR (thin film): 2955, 2897, 2857, 1740, 1710, 1438, 1401, 1373, 1253, 1199, 1162, 
1082, 1049, 840, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 6.97 (dd, J= 17.5, 10.5 Hz, 1H), 6.35 
(dd, J= 17.5, 2.0 Hz, 1H), 5.70 (dd, J= 10.5, 2.0 Hz, 1H), 4.16-4.12 (m, 1H), 3.66 (s, 3H), 2.56 
(dd, J= 15.0, 7.5 Hz, 1H), 2.47 (dt, J= 7.0, 3.0 Hz, 2H), 2.35 (dd, J= 15.0, 4.5 Hz, 1H), 2.32 (t, 
J= 7.0 Hz, 2H), 1.91-1.83 (m, 2H), 1.72 (dt, J= 13.0, 5.0 Hz, 1H), 1.54 (dt, J= 13.0, 4.5 Hz, 1H), 
1.47-1.36 (m, 2H), 1.35 (s, 3H), 0.84 (s, 9H), 0.13 (s, 9H), 0.04 (s, 3H), -0.02 (s, 3H); 
13
C NMR 
(125 MHz, CDCl3): δ 208.6, 202.6, 173.5, 130.7, 129.0, 81.4, 68.8, 51.5, 49.7, 43.4, 35.9, 33.0, 
31.5, 25.8, 24.4, 18.6, 17.9, 2.2, -4.6, -4.8; HRMS (ES+) m/z calcd for C24H46O6Si2Na [(M + 
Na)
+
]: 509.2731; found: 509.2696. 
 
 
 
(S,E)-7-(4-Methoxybenzyloxy)-5-methylhepta-1,5-dien-4-ol (95): To a stirred solution of 1.15 
mL of TiCl4 (1.15 mmol, 0.05 equiv, 1.0 M solution in CH2Cl2) in 23 mL of CH2Cl2 at 0°C was 
added Ti(O
i
Pr)4 (1.0 mL, 3.5 mmol, 0.15 equiv) dropwise.  The resulting solution was allowed to 
warm to ambient temperature and stirred for 1h.  0.533 g of Ag2O (2.30 mmol, 0.1 equiv) was 
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added into the reaction and the suspension was vigorously stirred overnight with exclusion of 
light.  The mixture was then diluted with 46 mL of CH2Cl2 and 1.32 g of (S)-BINOL (4.60 
mmol, 0.2 equiv) was added into the reaction in one portion.  The reaction was stirred at ambient 
temperature for 2h before being cooled to −15 °C.  The reaction was then treated sequentially 
with 4.63 g of aldehyde 93
33
 (21.0 mmol, 1.0 equiv) and 11.0 mL of allyltributylstannane (35.0 
mmol, 1.7 equiv).  The reaction was then allowed to warm to 0 °C and stirred for 6h.  The 
reaction was quenched with 70 mL of saturated NaHCO3 aqueous solution and the organic phase 
was separated.  The aqueous phase was extracted with Et2O (2 X 60 mL) and the combined 
organic extracts were filtered through a short pad of celite.  After concentrating the filtrate under 
reduced pressure, the crude residue thus obtained was purified via flash chromatography on silica 
gel (1 L of 15% EtOAc in hexanes then 1 L of 25% EtOAc in hexanes) to afford 4.0 g of the 
titled compound 95 (86%) as a clear oil.      
  −0.93 (c 4.1, CHCl3); IR (thin film): 3416, 3000, 
2934, 2858, 1612, 1513, 1462, 1365, 1302, 1248, 1175, 1035, 915, 820 cm
-1
; 
1
H NMR (400 
MHz, CDCl3): δ 7.28 (d, J= 8.8 Hz, 2H), 6.89 (d, J= 8.8 Hz, 2H), 5.80 (ddt, J= 17.2, 10.0, 7.2 
Hz, 1H), 5.66 (t, J= 6.8 Hz, 1H), 5.17-5.11 (m, 2H), 4.46 (s, 2H), 4.11-4.09 (m, 1H), 4.06 (d, J= 
6.8 Hz, 2H), 3.82 (s, 3H), 2.40-2.27 (m, 2H), 1.79 (br s, 1H), 1.66 (s, 3H); 
13
C NMR (125 MHz, 
CDCl3): δ 159.2, 140.7, 134.6, 130.4, 129.4, 122.6, 117.9, 113.8, 75.8, 71.9, 66.0, 55.3, 39.8, 
12.3; HRMS (ES+) m/z calcd for C16H22O3Na [(M + Na)
+
]: 285.1467; found: 285.1476. 
 
 
 
 (S,E)-tert-Butyl{[7-(4-methoxybenzyloxy)-5-methylhepta-1,5-dien-4-
yl]oxy}dimethylsilane: To a stirred solution of 4.16 g of alcohol 95 (16.0 
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mmol, 1.0 euqiv) in 60 mL of CH2Cl2 at −50 °C was added 2.8 mL of 2,6-lutidine (24 mmol, 1.5 
equiv) followed by 4.4 mL of TBSOTf (19 mmol, 1.2 equiv) slowly.  The reaction was stirred at 
this temperature for 1h and quenched by adding 50 mL of saturated NaHCO3 aqueous solution.  
After separating the organic phase, the aqueous phase was extracted with CH2Cl2 (2 X 40 mL).  
The combined organic extracts were dried over Na2SO4, filtered and concentrated.  The crude 
material was purified via flash column chromatography on silica gel (5% EtOAc in hexanes) to 
afford 5.37 g of the titled compound (89%) as a clear oil.      
  −0.430 (c 1.87, CHCl3); IR (thin 
film): 2954, 2931, 2856, 1613, 1513, 1465, 1250, 1173, 1074, 1038, 1004, 914, 835, 776 cm
-1
; 
1
H NMR (400MHz, CDCl3): δ 7.28 (d, J= 8.8 Hz, 2H), 6.90 (d, J= 8.8 Hz, 2H), 5.77 (ddt, J= 
17.2, 10.4, 6.8 Hz, 1H), 5.56 (t, J= 6.8 Hz, 1H), 5.08-5.00 (m, 2H), 4.44 (s, 2H), 4.09-4.06 (m, 
3H), 3.82 (s, 3H), 2.35-2.21 (m, 2H), 1.62 (s, 3H), 0.91 (s, 9H), 0.07 (s, 3H), 0.03 (3H); 
13
C 
NMR (100 MHz, CDCl3): δ 156.2, 141.3, 135.4, 130.7, 129.3, 122.2, 116.4, 113.8, 77.8, 71.4, 
65.9, 55.3, 41.2, 25.8, 18.2, 11.7, -4.6, -4.9; HRMS (ASAP) m/z calcd for C22H35O3Si [(M−H)
+
]: 
375.2362; found: 375.2355. 
 
 
 
 (S,E)-3-(tert-butyldimethylsilyloxy)-6-(4-methoxybenzyloxy)-4-
methylhex-4-enal (99): To a 0 °C solution of 3.0 g of the diene (8.0 
mmol, 1.0 equiv) in a mixed solvent of 
t
BtOH/acetone/H2O (16 mL/16 
mL/4 mL, 4:4:1) were added 0.937 g of 4-methylmorpholine N-oxide (8.00 mmol, 1.0 equiv) and 
a few crystals of osmium tetroxide sequentially.  The mixture was stirred at this temperature for 
4h and quenched with 40 mL of saturated Na2SO3 aqueous solution.  The mixture was extracted 
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with EtOAc (3 X 30 mL) and the combined organic extracts were washed with brine, dried over 
MgSO4, filtered and concentrated.  The crude product was used without further purification. 
             The crude diol obtained above was dissolved in a 1:1 mixture of THF and H2O (16 mL, 
16 mL).  3.42 G of sodium periodate (16.0 mmol, 2.0 equiv) was added in one portion. The 
reaction was stirred at ambient temperature for 2h and then filtered through a short pad of celite.  
The solid cake was rinsed repeatedly with Et2O and H2O.  The filtrate was transferred to a 
separatory funnel and the aqueous phase was separated.  The organic phase was washed 
sequentially with H2O and brine and then dried over MgSO4, filtered and concentrated.  The 
crude material was purified via flash column chromatography on silica gel (8% EtOAc in 
hexanes then 13% EtOAc in hexanes) to afford 2.48 g of titled compound 99 (82% in 2 steps) as 
a clear oil.      
   −1.00 (c 16.0, CHCl3); IR (thin film): 2954, 2931, 2895, 2856, 1726, 1613, 
1513, 1465, 1250, 1174, 1085, 1038, 1004, 837, 778 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 9.77 
(dd, J= 3.0, 2.5 Hz, 1H), 7.28 (d, J= 8.5 Hz, 2H), 6.90 (d, J= 9.0 Hz, 2H), 5.69 (t, J= 6.5 Hz, 
1H), 4.60 (dd, J= 8.0, 4.0 Hz, 1H), 4.44 (s, 2H), 4.05 (d, J= 6.5 Hz, 2H), 3.82 (s, 3H), 2.69 (ddd, 
J= 15.5, 8.0, 3.0 Hz, 1H), 2.45 (ddd, J= 15.5, 4.0, 2.0 Hz, 1H), 1.64 (d, J= 1.0 Hz, 3H), 0.89 (s, 
9H), 0.08 (s, 3H), 0.05 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 201.6, 159.2, 139.9, 130.4, 
129.4, 123.1, 113.8, 73.3, 71.8, 65.8, 55.3, 50.0, 25.7, 18.1, 11.9, -4.6, -5.2; HRMS (ES+) calcd 
for C21H34O4SiNa [(M + Na)
+
]: 401.2124; found: 401.2114. 
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(3R,4R,6S,E)-6-(tert-Butyldimethylsilyloxy)-9-(4-methoxybenzyloxy)-3,7-dimethylnona-1,7-
dien-4-ol (101): To a −78°C solution of 0.404 g of freshly sublimed tBuOK (3.60 mmol, 1.2 
equiv)  in 25 mL of THF was cannulated 0.85 mL of (Z)-2-butene (9.0 mmol, 3.0 equiv, 0.094 
mL/mol, condensed at −78 °C) followed by adding 2.25 mL of  nBuLi (3.6 mmol, 1.2 equiv) via 
syringe.  The bright yellow suspension was stirred at −78 °C for 5 min, −45 °C for 10 min and 
then −78 °C for 15 min.  A solution of 1.33 g of (−)-Ipc2BOMe (4.20 mmol, 1.4 equiv) in 3 mL 
of Et2O was cannulated into the reaction.  The colorless solution was stirred for 30 min 
whereupon 0.56 mL of BF3·Et2O (4.5 mmol, 1.5 equiv) was added immediately followed by a 
solution of 1.1 g of aldehyde 99 (3.0 mmol, 1.0 equiv) in 4 mL of THF.  The reaction was stirred 
at −78 °C for 3 h and then quenched by adding 8 mL of 3 N NaOH aqueous solution.  4 mL of 
H2O2 30% aqueous solution was carefully added dropwise (Caution: gas evolution).  The mixture 
was then allowed to warm to ambient temperature and stirred for 12h.  The mixture was then 
diluted with 60 mL of EtOAc and washed sequentially with 30 mL of H2O and 30 mL of brine.  
The organic phase was dried over MgSO4, filtered and concentrated.  The crude material was 
purified via flash column chromatography on silica gel (8% EtOAc in hexanes then 13% EtOAc 
in hexanes) to afford 0.95 g of the titled compound (73%) in a form of two diastereomers which 
could be separated at later stage.  The characterization of the major diastereomer 101 is: 
    
  −0.640 (c 5.30, CHCl3); IR (thin film): 3466, 2954, 2930, 2857, 1612, 1513, 1463, 1363, 
1302, 1251, 1173, 1073, 1005, 920, 836, 778 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.27 (d, J= 
9.0 Hz, 2H), 6.89 (d, J= 9.0 Hz, 2H), 5.80 (ddd, J= 18.0, 10.5, 7.5 Hz, 1H), 5.59 (t, J= 6.0 Hz, 
1H), 5.09-5.02 (m, 2H), 4.44 (d, J= 2.0 Hz, 2H), 4.28 (dd, J= 8.5, 5.0 Hz, 1H), 4.03 (d, J= 6.5 
Hz, 2H), 3.82 (s, 3H), 3.62 (ddd, J= 8.5, 5.5, 3.0 Hz, 1H), 2.28-2.22 (m, 1H), 1.03 (d, J= 6.5 Hz, 
3H), 0.91 (s, 9H), 0.12 (s, 3H), 0.03 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 159.2, 141.1, 141.0, 
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130.4, 129.3, 123.0, 114.9, 113.8, 79.4, 74.4, 71.9, 66.0, 55.3, 43.8, 39.5, 25.8, 18.0, 15.1, 11.6, -
4.3, -5.1; HRMS (ES+) m/z calcd for C25H42O4SiNa [(M + Na)
+
]: 457.2750; found: 457.2759. 
 
 
 
 (5R,7S)-5-[(R)-But-3-en-2-yl]-7-[(E)-4-(4-methoxybenzyloxy)but-
2-en-2-yl]-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-
disilaundecane (103): To a stirred −50 °C solution of 0.506 g of 
alcohol 101 (1.20 mmol, 1.0 euqiv) in 6 mL of CH2Cl2 was added 0.21 mL of 2,6-lutidine (1.8 
mmol, 1.5 equiv) followed by 0.33 mL of TBSOTf (1.4 mmol, 1.2 equiv) dropwise.  The 
reaction was stirred at this temperature for 1h and quenched by adding 6 mL of saturated 
NaHCO3 aqueous solution.  After separating the organic phase, the aqueous phase was extracted 
with CH2Cl2 (2 X 6 mL).  The combined organic extracts were dried over Na2SO4, filtered and 
concentrated.  The crude material was purified via flash column chromatography on silica gel 
(5% Et2O in hexanes) to afford 0.67 g of titled compound 103 (100%) as a clear oil.      
   0 (c 
1.23, CHCl3); IR (thin film): 2955, 2931, 2890, 2857, 1513, 1463, 1362, 1250, 1078, 1039, 1005, 
835, 774 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.28 (d, J= 8.5 Hz, 2H), 6.90 (d, J= 9.0 Hz, 2H), 
5.95-5.88 (m, 1H), 5.56 (t, J= 6.0 Hz, 1H), 5.06-4.99 (m, 2H), 4.45 (s, 2H), 4.14 (t, J= 6.5 Hz, 
1H), 4.06 (dd, J= 6.0, 3.0 Hz, 2H), 3.82 (s, 3H), 3.69 (dt, J= 6.0, 3.0 Hz, 1H), 2.38-2.34 (m, 1H), 
1.64 (t, J= 6.5 Hz, 2H), 1.60 (s, 3H), 0.95 (d, J= 7.0 Hz, 3H), 0.913 (s, 9H), 0.906 (s, 9H), 0.08 
(s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 159.2, 141.9, 
141.4, 130.6, 129.2, 122.8, 113.8, 113.7, 75.5, 72.5, 71.6, 66.0, 55.3, 41.7, 40.8, 26.0, 25.9, 18.1, 
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13.3, 11.3, -4.2, -4.3, -4.5, -4.9; HMRS (ES+) m/z calcd for C31H56O4NaSi2 [(M+Na)
+
]: 
571.3615; found: 571.3636. 
 
 
 
 (3R,4R,6S,E)-4,6-Bis(tert-butyldimethylsilyloxy)-9-(4-
methoxybenzyloxy)-3,7-dimethylnon-7-en-1-ol : To a stirred 0 
°C solution of 0.61 g of diene 103 (1.1 mmol, 1.0 equiv) in 10 mL of Et2O was added 0.256 g of 
9-BBN dimer (1.05 mmol, 0.94 equiv) in one portion.  The reaction was warmed to ambient 
temperature and stirred for 5h.  The reaction was cooled to 0 °C and 12 mL of 1 N NaOH 
aqueous solution was added followed by careful addition of 12 mL of H2O2 30% aqueous 
solution.  The resulting mixture was warmed to ambient temperature and stirred for 15 min and 
then poured into a separatory funnel equipped with 30 mL of saturated NaHCO3 aqueous 
solution and 30 mL of CH2Cl2.  The organic phase was separated and the aqueous phase was 
extracted with CH2Cl2 (3 X 20 mL).  The combined organic extracts were dried over Na2SO4, 
filtered and concentrated.  The crude material was purified via flash column chromatography on 
silica gel (5% EtOAc in hexanes then 15% EtOAc in hexanes) to afford 0.58 g of the titled 
compound (91%) as a clear oil.      
  −0.0300 (c 3.39, CHCl3); IR (thin film): 3426, 2954, 2931, 
2886, 2857, 1613, 1514, 1464, 1385, 1362, 1302, 1251, 1174, 1059, 1007, 940, 836, 775 cm
-1
; 
1
H NMR (400 MHz, CDCl3): δ 7.27 (d, J= 8.8 Hz, 2H), 6.89 (d, J= 8.4 Hz, 2H), 5.55 (t, J= 6.0 
Hz, 1H), 4.44 (s, 2H), 4.12 (t, J= 6.4 Hz, 1H), 4.04 (d, J= 6.4 Hz, 2H), 3.82 (s, 3H), 3.73-3.68 
(m, 1H), 3.65-3.59 (m, 1H), 1.87 (br s, 1H), 1.79-1.71 (m, 2H), 1.67 (dt, J= 6.4, 2.8 Hz, 2H), 
1.58 (s, 3H), 1.48-1.39 (m, 1H), 0.91 (s, 9H), 0.89 (s, 9H), 0.84 (d, J= 6.4 Hz, 3H), 0.09 (s, 3H), 
 78 
0.06 (s, 3H), 0.05 (s, 3H), 0.00 (m, 3H); 
13
C NMR (125 MHz, CDCl3): δ 159.2, 141.2, 130.5, 
129.2, 123.0, 113.8, 75.6, 72.9, 71.6, 65.9, 61.6, 55.3, 39.8, 36.2, 34.8, 25.9, 25.8, 18.13, 18.10, 
14.7, 11.2, -4.1, -4.2, -4.5, -4.9; HRMS (ES+) m/z calcd for C31H58O5Si2Na [(M + Na)
+
]: 
589.3721; found: 589.3727. 
 
 
 
 (3R,4R,6S,E)-4,6-Bis(tert-butyldimethylsilyloxy)-9-(4-
methoxybenzyloxy)-3,7-dimethylnon-7-enal (48): To a stirred 
solution of 113 mg of the alcohol (0.200 mmol, 1.0 equiv) in 2 mL 
of CH2Cl2 was added 0.21 mL of 2,6-lutidine (1.8 mmol, 9.0 equiv) followed by 127 mg of 
Dess-Martin periodinane (0.300 mmol, 1.5 equiv) in one portion.  The heterogeneous mixture 
was stirred vigorously at ambient temperature for 0.5 h and quenched by a 1:1 mixture of 
saturated NaHCO3 and Na2S2O3 aqueous solution (9 mL, 9 mL).  The mixture was extracted with 
CH2Cl2 (3 X 15 mL).  The combined organic extracts were dried over Na2SO4, filtered and 
concentrated.  The crude material was purified via flash chromatography on silica gel (6% 
EtOAc in hexanes) to afford 100 mg of titled compound 48 (88%) as a clear oil.      
   −0.910 (c 
1.32, CHCl3); IR (thin film): 2955, 2931, 2887, 2856, 1727, 1613, 1513, 1464, 1385, 1362, 1250, 
1173, 1080, 1039, 1007, 938, 836, 775 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 9.79-9.78 (m, 1H), 
7.27 (d, J= 9.0 Hz, 2H), 6.89 (d, J= 8.5 Hz, 2H), 5.55 (t, J= 6.0 Hz, 1H), 4.44 (d, J= 2 Hz, 2H), 
4.12 (t, J= 7.0 Hz, 1H), 4.05 (dd, J= 6.0, 2.5 Hz, 2H), 3.82 (s, 3H), 3.65 (dt, J= 6.0, 2.0 Hz, 1H), 
2.57-2.54 (m, 1H), 2.33-2.24 (m, 2H), 1.67-1.55 (m, 2H), 1.58 (s, 3H), 0.90 (s, 9 H), 0.89 (s, 
9H), 0.87 (d, J= 7.0 Hz, 3H), 0.076 (s, 3H), 0.053 (s, 3H), 0.039 (s, 3H), 0.006 (s, 3H); 
13
C NMR 
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(125 MHz, CDCl3): δ 202.6, 159.2, 141.0, 130.5, 129.2, 123.3, 113.8, 75.4, 72.1, 71.6, 66.0, 
55.3, 47.5, 39.7, 32.2, 25.9, 25.8, 18.1, 18.0, 14.0, 11.2, -4.2, -4.3, -4.5, -5.0; HRMS (ES+) m/z 
calcd for C31H56O5Si2Na [(M+Na)
+
]: 587.3564; found: 587.3600. 
 
 
 
(7S,10R,16R,17R,19S,E)-Methyl-7,17,19-tris(tert-butyldimethylsilyloxy)-22-(4 
methoxybenzyloxy)-10,16,20-trimethyl-5,11,14-trioxo-10-(trimethylsilyloxy)docos-20-
enoate (115): Into a vial with a Teflon cap and a magnetic stirring bar were charged 91.4 mg of 
aldehyde 48 (0.160 mmol, 1.0 equiv) and 120 mg of enone 47 (0.240 mmol, 1.5 equiv).  The vial 
was transferred to the glove box, where 12 mg of thiozolium salt 119 (0.032 mmol, 0.2 equiv) 
and 9.0 mg of anhydrous K2CO3 (0.064 mmol, 0.4 equiv) were weighed out.  The vial was 
removed from the glove box and 0.4 mL of THF was added.  The suspension was stirred in a 
pre-heated oil bath at 70 °C for 3h (The solid went into solution and the reaction turned red after 
10 min).  The reaction mixture was directly loaded on a silica gel column and purified (100 mL 
of 7% EtOAc in hexanes, 200 mL of 13% EtOAc in hexanes and then 100 mL of 18% EtOAc in 
hexanes) to afford 172 mg of titled compound 115 (100%) as a light yellow oil.      
  +1.50 (c 
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1.23, CHCl3); IR (thin film): 2955, 2931, 2895, 2856, 1740, 1715, 1251, 1080, 1007, 837, 776 
cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.26 (d, J= 9.0 Hz, 2H), 6.88 (d, J= 9.0 Hz, 2H), 5.54 (t, J= 
6.0 Hz, 1H), 4.43 (d, J= 1.5 Hz, 2H), 4.14-4.11 (m, 2H), 4.04 (t, J= 6.0 Hz, 2H), 3.81 (s, 3H), 
3.67 (s, 3H), 3.58 (dt, J= 6.0, 2.5 Hz, 1H), 2.92 (ddd, J= 19.0, 7.0, 5.5 Hz, 1H), 2.81 (ddd, J= 
19.0, 7.0, 5.5 Hz, 1H), 2.66 (ddd, J= 18.0, 7.5, 5.5 Hz, 1H), 2.61-2.53 (m, 3H), 2.49 (dt, J= 7.0, 
3.5 Hz, 2H), 2.39-2.34 (m, 2H), 2.33 (t, J= 7.5 Hz, 2H), 2.24-2.19 (m, 1H), 1.87 (d qent, J= 7.5, 
3.5 Hz, 2H), 1.79-1.73 (m, 1H), 1.66-1.61 (m, 1H), 1.59-1.49 (m, 3H), 1.57 (s, 3H), 1.33 (s, 3H), 
1.28-1.24 (m, 1H), 0.90 (s, 9H), 0.88 (s, 9H), 0.85 (s, 9H), 0.79 (d, J= 7.0 Hz, 3H), 0.17 (s, 9H), 
0.065 (s, 3H), 0.054 (s, 3H), 0.053 (s, 3H), 0.035 (s, 3H), 0.003 (s, 3H), -0.004 (s, 3H); 
13
C NMR
 
(125 MHz, CDCl3): δ 214.2, 209.0, 208.8, 173.6, 159.1, 141.1, 130.6, 129.2, 123.2, 113.8, 82.6, 
75.5, 72.5, 71.5, 68.9, 65.9, 55.3, 51.5, 49.8, 45.9, 43.5, 39.8, 36.6, 36.3, 33.3, 33.0, 31.7, 31.6, 
26.0, 25.9, 25.8, 18.6, 18.14, 18.07, 18.0, 13.9, 11.0, 2.4, -4.2, -4.3, -4.47, -4.52, -4.8, -5.0; 
HRMS (TOF ES+) m/z calcd for C55H102O11Si4Na [(M + Na)
+
]: 1073.6397; found: 1073.6397. 
 
 
 
Bis-spiroketal (125): To a stirred solution of 136 mg of ketone 115 (0.130 mmol, 1.0 equiv) in 3 
mL of MeOH was added 15 mg of (1R)-(−)-10-camphorsulfonic acid (0.065 mmol, 0.5 equiv) in 
one portion.  The reaction was stirred at ambient temperature for 16 h.  The solvent was removed 
under reduced pressure and the residue was purified via flash column chromatography on silica 
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gel (150 mL of 50% EtOAc in hexanes then 300 mL of 70% EtOAc in hexanes) to afford 57.7 
mg of titled compound 125 (72%) as a light yellow oil.  The characterization of the major 
diastereomer trans-125 is:      
  + 2.8 (c 0.74, CHCl3); IR (thin film): 3468, 2944, 1737, 1714, 
1612, 1513, 1442, 1379, 1301, 1249, 1207, 1174, 1073, 1033, 1003, 975, 930, 867, 820 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3): δ 7.27 (d, J= 8.5 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 5.68 (t, J= 6.5 Hz, 
1H), 4.45 (s, 2H), 4.30-4.22 (m, 2H), 4.20 (dd, J= 8.5, 4.0 Hz, 1H), 4.05 (d, J= 6.5 Hz), 3.81 (s, 
3H), 3.67 (s, 3H), 3.23 (brs, 1H), 2.58 (dd, J= 15.0, 9.0 Hz, 2H), 2.50 (q, J= 7.5 Hz, 2H), 2.45 
(brs, 1H), 2.39-2.30 (m, 5H), 2.13 (dt, J= 12.5, 7.5 Hz, 1H), 1.97 (dd, J= 12.5, 7.5 Hz, 1H), 1.89 
(t, J= 7.5 Hz, 2H), 1.87-1.81 (m, 1H), 1.76 (dd, J= 13.0, 8.5 Hz, 1H), 1.68-1.63 (m, 6H), 1.62-
1.55 (m, 2H), 1.50-1.40 (m, 1H), 1.22 (s, 3H), 0.96 (d, J= 7.0 Hz); 
13
C NMR (125 MHz, CDCl3): 
δ 208.4, 173.6, 159.2, 140.9, 130.5, 129.4, 122.3, 115.3, 113.8, 110.7, 81.8, 76.5, 71.9, 68.5, 
67.1, 66.0, 55.3, 51.6, 48.4, 43.5, 42.7, 35.7, 35.4, 35.2, 35.1, 33.0, 30.6, 30.1, 21.1, 18.6, 14.3, 
12.4; HRMS (TOF ES+) m/z calcd for C34H50O10Na [(M+Na)
+
]: 641.3302; found: 641.3309. 
 
 
 
Bis-spiroketal (trans-127): Generating the methylenation reagent: A flame-dried 2 dram vial 
were charged with 59 mg of activated zinc (0.90 mmol, 1.8 equiv) and 4.1 mg of PbI2 (0.0089 
mmol, 0.018 equiv) under N2 atmosphere.  1mL of THF was added and the resulting suspension 
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was stirred vigorously at ambient temperature whereupon one drop of distilled TMSCl was 
added.  The mixture was stirred for 15 min before being cooled to 0 °C.  40 µL of CH2I2 (0.50 
mmol, 1.0 equiv) was added dropwise and the black suspension thus generated was stirred 
vigorously for 2h at 0 °C.  0.1 mL of TiCl4 (0.1 mmol, 0.2 equiv, 1.0 M solution in CH2Cl2) was 
added into the reaction and the greenish brown mixture was allowed to warm to ambient 
temperature and stirred for 30 min to afford the methylenation reagent.  13.9 mg of 125 (0.022 
mmol, 0.22 equiv to TiCl4) was added into the vial containing the methylenation reagent at 0 °C 
as a solution of THF (0.5 mL).  The reaction was stirred at 0 °C for 3h and quenched by 
saturated Rochelle’s salts aqueous solution and diluted with EtOAc.  The mixture was allowed to 
warm to ambient temperature and stirred until two homogenous layers resulted (~1h).  The 
organic phase was separated and the aqueous phase was extracted three times with EtOAc.  The 
combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated.  
The crude material was purified via flash chromatography on a pipet silica gel column, eluting 
with 5 mL of 30% EtOAc in hexanes followed by 10 mL of 50% EtOAc in hexanes and 10 mL 
of 70% EtOAc in hexanes to afford 8.0 mg of titled compound 127 (58%) as clear oil.  The 
characterization of the major diastereomer trans-127 is:      
  +2.20 (c 1.64, CHCl3); IR (thin 
film): 3459, 2938, 1737, 1612, 1513, 1441, 1377, 1337, 1301, 1248, 1173, 1071, 1035, 1002, 
979, 932, 868, 822 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.28 (d, J= 8.0 Hz, 2H), 6.88 (d, J= 8.0 
Hz, 2H), 5.69 (t, J= 6.5 Hz, 1H), 4.80 (s, 1H), 4.79 (s, 1H), 4.45 (s, 2H), 4.27 (ddd, J= 10.0, 7.0, 
3.0 Hz, 1H), 4.20 (dd, J= 8.5, 4.0 Hz, 1H), 4.05 (d, J= 6.5 Hz, 2H), 3.94-3.89 (m, 1H), 3.81 (s, 
3H), 3.68 (s, 3H), 2.54 (heptet, J= 7.0 Hz, 1H), 2.38 (dd, J= 12.5, 7.5 Hz, 1H), 2.32 (t, J= 7.5 Hz, 
2H), 2.29-2.27 (m, 1H), 2.21 (dd, J= 12.5, 7.5 Hz, 1H), 2.16 (dd, J= 15.0, 8.0 Hz, 1H), 2.07-2.04 
(m, 3H), 1.99 (dd, J= 12.5, 7.5 Hz, 1H), 1.85-1.81 (m, 1H), 1.79-1.75 (m, 3H), 1.71 (dd, J= 12.5, 
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7.5 Hz, 1H), 1.66-1.64 (m, 4H), 1.62-1.55 (m, 3H), 1.42 (dq, J= 13.0, 4.0 Hz, 1H), 1.23 (s, 3H), 
0.95 (d, J= 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 174.1, 159.2, 145.7, 140.9, 130.6, 
129.4, 122.3, 115.1, 113.8, 111.4, 110.8, 81.5, 76.5, 71.9, 68.9, 68.8, 66.0, 55.3, 51.5, 43.6, 41.7, 
35.8, 35.7, 35.6, 35.4, 35.3, 33.5, 30.8, 30.3, 22.7, 21.2, 14.4, 12.4; HRMS (TOF ES+) m/z calcd 
for C35H52O9Na [(M+Na)
+
]: 639.3509; found: 639.3508.  
 
 
 
Bis-spiroketals (trans-45) and (cis-45): To a stirred solution of 127 (8.0 mg, 0.013 mmol, 1.0 
equiv) and 2,6-lutidine (18 µL, 0.16 mmol, 12.0 equiv) in 0.5 mL of CH2Cl2 at 0 °C was added 
TBSOTf (18 µL, 0.078 mmol, 6.0 equiv) dropwise.  The reaction was stirred for 1.5h until full 
consumption of the starting material was observed.  The reaction was quenched by saturated 
NaHCO3 aqueous solution and warmed to ambient temperature.  The organic phase was 
separated and the aqueous phase was extracted three times with CH2Cl2.  The combined organic 
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extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The 
1
H NMR of 
the crude products showed 1.5:1 ratio of cis-45 to trans-45.  The crude material was purified via 
flash chromatography on pipet silica gel column, eluting with 5 mL of 5% EtOAc in hexanes 
followed by 10 mL of 10% EtOAc in hexanes and 10 mL of 15% EtOAc in hexanes to afford 4.5 
mg of compound trans-45 (41%) and 4.3 mg of compound cis-45 (39%).  Full characterization 
for compound trans-45:     
   +3.7 (c 0.62, benzene); IR (thin film): 2953, 2931, 2855, 1742, 
1513, 1463, 1442, 1250, 1162, 1075, 1040, 965, 867, 836, 774 cm
-1
; 
1
H NMR (600 MHz, C6D6): 
δ 7.29 (d, J= 9.0 Hz, 2H), 6.82 (d, J= 9.0 Hz, 2H), 5.88 (t, J= 6.0 Hz, 1H), 4.87 (s, 1H), 4.83 (d, 
J= 1.2 Hz, 1H), 4.45-4.39 (m, 3H), 4.23 (dt, J= 8.4, 5.4 Hz, 1H), 4.05 (d, J= 6.6 Hz, 2H), 3.95 
(dddd, J= 11.4, 8.4, 4.8, 3.6 Hz, 1H), 3.35 (s, 3H), 3.30 (s, 3H), 2.52-2.48 (m, 1H), 2.44 (dt, J= 
12.0, 8.4 Hz, 1H), 2.32 (dd, J= 13.2, 7.2 Hz, 1H), 2.25 (dt, J= 12.0, 7.8 Hz, 1H), 2.23-2.15 (m, 
2H), 2.15 (t, J= 7.8 Hz, 2H), 2.07 (ddd, J= 12.6, 9.0, 1.8 Hz, 1H), 2.03 (t, J= 7.8 Hz, 2H), 1.99 
(dd, J= 14.4, 4.8 Hz, 1H), 1.83 (ddd, J= 13.8, 8.4, 5.4 Hz, 1H), 1.76 (pent, J= 7.8 Hz, 2H), 1.70 
(ddd, J= 7.8, 3.6, 1.8 Hz, 1H), 1.69-1.67 (m, 1H), 1.66 (s, 3H), 1.64 (dd, J= 13.2, 8.4 Hz, 1H), 
1.54 (ddd, J= 12.0, 4.2, 3.0 Hz, 1H), 1.37-1.34 (m, 1H), 1.32 (s, 3H), 1.32-1.29 (m, 1H), 1.15 (s, 
9H), 1.03 (s, 9H), 0.82 (d, J= 7.2 Hz, 3H), 0.34 (s, 3H), 0.23 (s, 3H), 0.16 (s, 3H), 0.14 (s, 3H); 
13
C NMR (125 MHz, C6D6): δ 173.2, 159.7, 146.5, 140.6, 131.3, 129.4, 124.4, 115.1, 114.1, 
111.8, 110.0, 78.2, 76.3, 73.0, 72.0, 68.8, 66.3, 54.7, 50.9, 46.4, 42.4, 37.6, 36.2, 36.0, 34.8, 34.7, 
33.5, 30.9, 30.8, 26.5, 26.2, 25.2, 23.1, 18.6, 18.4, 14.4, 11.1, -1.6, -1.7, -4.3, -4.7; HRMS (TOF 
ES+) m/z calcd for C47H80O9Si2Na [(M+Na)
+
]: 867.5239; found: 867.5237.  Full characterization 
for compound cis-45:     
   +2.8 (c 0.54, benzene); IR (thin film): 2952, 2931, 2856, 1741, 1513, 
1462, 1250, 1171, 1135, 1039, 1010, 876, 835, 774; 
1
H NMR (600 MHz, C6D6): δ 7.30 (d, J= 8.4 
Hz, 2H), 6.83 (d, J= 9.0 Hz, 2H), 5.92 (app t, J= 6.0 Hz, 1H), 5.24 (s, 1H), 5.04 (s, 1H), 4.52 (dd, 
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J= 7.8, 6.0 Hz, 1H), 4.42 (d, J= 4.2 Hz, 2H), 4.36 (dq, J= 7.2, 3.6 Hz, 1H), 4.07 (dd, J= 6.0, 4.2 
Hz, 2H), 3.98 (dt, J= 10.2, 4.8 Hz, 1H), 3.35 (s, 3H), 3.31 (s, 3H), 2.40 (ddd, J= 12.0, 10.8, 7.8 
Hz, 1H), 2.33 (dd, J= 15.0, 7.8 Hz, 1H), 2.30-2.24 (m, 2H), 2.25 (t, J= 7.2 Hz, 2H), 2.20 (q, J= 
7.2 Hz, 1H), 2.13 (dd, J= 15.0, 3.6 Hz, 1H), 2.10-2.00 (m, 4H), 1.90 (pent, J= 7.2 Hz, 2H), 1.88-
1.87 (m, 1H), 1.79-1.73 (m, 2H), 1.71 (ddd, J= 11.4, 8.4, 2.4 Hz, 1H), 1.68 (s, 3H), 1.55 (ddd, J= 
12.0, 4.2, 2.4 Hz, 1H), 1.50 (dddd, J= 13.2, 4.8, 2.4, 2.4 Hz, 1H), 1.44-1.36 (m, 1H), 1.30 (s, 
3H), 1.03 (s, 9H), 0.99 (d, J= 6.6 Hz, 3H), 0.99 (s, 9H), 0.20 (s, 3H), 0.17 (s, 3H), 0.167 (s, 3H), 
0.11 (s, 3H); 
13
C NMR (125 MHz, C6D6): δ 173.1, 159.4, 145.9, 140.0, 131.0, 129.1, 124.3, 
116.3, 113.7, 111.8, 109.5, 78.9, 76.3, 73.2, 71.6, 68.2, 65.9, 54.4, 50.5, 45.5, 42.1, 37.0, 36.9, 
36.1, 35.5, 34.4, 33.3, 30.7, 30.6, 25.9, 25.8, 24.1, 22.9, 18.1, 13.9, 10.8, -1.9, -2.1, -4.6, -4.9; 
HRMS (TOF ES+) m/z calcd for C47H80O9Si2Na [(M+Na)
+
]: 867.5239; found: 867.5228.  The 
relative stereochemistry of both trans-45 and cis-45 was established by NOESY. 
 
             (S)-(S,E)-7-(4-Methoxybenzyloxy)-5-methylhepta-1,5-dien-4-
yl 2-methoxy-2-phenylacetate (181): To a stirred solution of secondary 
alcohol 95 (26.3 mg, 0.100 mmol, 1.0 equiv), (S)-(+)-α-
methoxypenylacetic acid (25.0 mg, 0.150 mmol, 1.5 equiv), and DMAP 
(12.2 mg, 0.100 mmol, 1.0 equiv) in 1.0 mL of CH2Cl2 at ambient temperature was added 31.0 
mg of N,N’-dicyclohexylcarbodiimide (0.150 mmol, 1.5 equiv) in one portion.  The reaction was 
stirred overnight. After evaporating the solvent, the crude material was purified via flash 
chromatography on silica gel (12% EtOAc in hexanes) to afford 40.5 mg of the titled compound 
(99%) as a clear oil.  
1
H NMR (500 MHz, CDCl3): δ 7.44-7.42 (m, 2H), 7.35-7.28 (m, 3H), 7.21 
(d, J= 8.0 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 5.68 (ddt, J= 7.0, 10.5, 17.5 Hz, 1H), 5.44 (t, J= 6.5 
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Hz, 1H), 5.26 (t, J= 7.0 Hz, 1H), 5.09-5.03 (m, 2H), 4.76 (s, 1H), 4.30 (s, 2H), 3.90 (t, J= 6.5 Hz, 
2H), 3.81 (s, 3H), 3.42 (s, 3H), 2.45-2.35 (m, 2H), 1.38 (s, 3H).  
 
            (R)-(S,E)-7-(4-Methoxybenzyloxy)-5-methylhepta-1,5-dien-4-
yl 2-methoxy-2-phenylacetate (182): To a stirred solution of secondary 
alcohol 95 (26.3 mg, 0.100 mmol, 1.0 equiv), (R)-(−)-α-
methoxypenylacetic acid (25.0 mg, 0.150 mmol, 1.5 equiv), and DMAP 
(12.2 mg, 0.100 mmol, 1.0 equiv) in 1.0 mL of CH2Cl2 at ambient temperature was added 31.0 
mg of N,N’-dicyclohexylcarbodiimide (0.150 mmol, 1.5 equiv) in one portion.  The reaction was 
stirred overnight. After evaporating the solvent, the crude material was purified via flash 
chromatography on silica gel (12% EtOAc in hexanes) to afford 35.8 mg of the titled compound 
(87%) as a clear oil.  
1
H NMR (500 MHz, CDCl3): δ 7.45-7.43 (m, 2H), 7.37-7.30 (m, 3H), 7.25 
(d, J= 8.5 Hz, 2H), 6.89 (d, J= 9.0 Hz, 2H), 5.64 (t, J= 6.0 Hz, 1H), 5.44 (dddd, J= 19.0, 12.5, 
9.5, 7.0 Hz, 1H), 5.24 (t, J= 6.5 Hz, 1H), 4.86-4.83 (m, 2H), 4.76 (s, 1H), 4.40 (s, 2H), 4.02 (d, 
J= 6.0 Hz, 2H), 3.81 (s, 3H), 3.42 (s, 3H), 2.33-2.23 (m, 2H), 1.60 (s, 3H).  
 
Proton numbering for O-methylmandelate esters 
Table 7: Chemical Shifts of Protons in O-Methylmandelate Esters 181 and 182 and Application 
of the Trost method (δS−δR).
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H# δ (S)-ester 181 δ (R)-ester 182 Δδ= δS−δR 
1 3.895 4.016 −0.121 
2 5.435 5.644 −0.209 
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3 1.380 1.596 −0.216 
5 2.451 
2.352 
2.334 
2.231 
+0.117 
+0.121 
6 5.678 5.438 +0.240 
The differences in chemical shifts indicate the absolute configuration of S at the C-4. 
 
 
(S)-3-Hydroxy-N-methoxy-N,6-dimethylhept-6-enamide (183): To 
a stirred solution of compound 57 (188 mg, 0.600 mmol, 1.0 equiv) 
in 2 mL of CH3CN at 0 °C was added 0.1 mL of HF acid (48 wt. % in 
water) dropwise.  The reaction was stirred at this temperature for 2.5h and quenched by saturated 
NaHCO3 aqueous solution.  The organic phase was separated and the aqueous phase was 
extracted three times with CH2Cl2.  The combined organic extracts were dried over anhydrous 
Na2SO4, filtered and concentrated.  The crude material was carried in the next step without 
further purification.  
 
      (S)-(S)-1-[Methoxy(methyl)amino]-6-methyl-1-oxohept-6-en-
3-yl 2-methoxy-2-phenylacetate (184): To a stirred solution of the 
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crude secondary alcohol (48.7 mg, 0.240 mmol, 1.0 equiv) in 2 mL of CH2Cl2 were added 60 mg 
of (S)-(+)-α-methoxypenylacetic acid (0.36 mmol, 1.5 equiv), 10 mg of DMAP (0.080 mmol, 
0.33 equiv) and 74 mg of N,N’-dicyclohexylcarbodiimide (0.36 mmol, 1.5 equiv) sequentially.  
The resulting mixture was stirred at ambient temperature overnight.  The solvent was removed 
under reduced pressure and the crude product was purified via flash chromatography on silica 
gel, eluting with 100 mL of 20% of EtOAc in hexanes followed by 200 mL of 30% of EtOAc in 
hexanes and 200 mL of 40% EtOAc in hexanes, to afford 66 mg of the titled compound (78% 
over two steps) as a clear oil.  
1
H NMR (500 MHz, CDCl3): δ 7.44 (dd, J= 8.0, 1.5 Hz, 2H), 
7.37-7.30 (m, 3H), 5.34 (pent, J= 6.4 Hz, 1H), 4.75 (s, 1H), 4.69 (s, 1H), 4.60 (d, J= 1.0 Hz, 1H), 
3.55 (s, 3H), 3.42 (s, 3H), 3.04 (s, 3H), 2.72 (dd, J= 15.0, 6.5  Hz, 1H), 2.50 (dd, J= 15.5, 6.0 Hz, 
1H), 1.97 (t, J= 8.0 Hz, 2H), 1.87-1.75 (m, 2H), 1.68 (s, 3H).  The ee value of the compound 183 
can be established as ≥ 95%, since only one diastereomer of 184 was observed in the spectrum.  
 
     (R)-(S)-1-[Methoxy(methyl)amino]-6-methyl-1-oxohept-6-en-3-
yl 2-methoxy-2-phenylacetate (185): To a stirred solution of the 
crude secondary alcohol (67.7 mg, 0.340 mmol, 1.0 equiv) in 3 mL of 
CH2Cl2 were added 85 mg of (R)-(−)-α-methoxypenylacetic acid (0.51 mmol, 1.5 equiv), 10 mg 
of DMAP (0.080 mmol, 0.24 equiv) and 105 mg of N,N’-dicyclohexylcarbodiimide (0.510 
mmol, 1.5 equiv) sequentially.  The resulting mixture was stirred at ambient temperature 
overnight.  The solvent was removed under reduced pressure and the crude product was purified 
via flash chromatography on silica gel, eluting with 100 mL of 20% of EtOAc in hexanes 
followed by 200 mL of 30% of EtOAc in hexanes and 200 mL of 40% EtOAC in hexanes, to 
afford 98.3 mg of the titled compound (84% over two steps) as a clear oil.  
1
H NMR (500 MHz, 
 89 
CDCl3): δ 7.44 (dd, J= 8.0, 1.5 Hz, 2H), 7.38-7.31 (m, 3H), 5.28-5.26 (m, 1H), 4.74 (s, 1H), 4.59 
(s, 1H), 4.38 (d, J= 1.0 Hz, 1H), 3.68 (s, 3H), 3.43 (s, 3H), 3.16 (s, 3H), 2.77 (dd, J= 15.0, 6.5 
Hz, 1H), 2.65 (dd, J= 15.0, 5.5 Hz, 1H), 1.78-1.59 (m, 4H), 1.54 (s, 3H). 
 
 
 
Proton numbering for O-methylmandelate esters 
Table 8: Chemical Shifts of Protons in O-Methylmandelate Esters 184 and 185 and Application 
of the Trost method (δS−δR). 
H# δ (S)-ester 184 δ (R)-ester 185 Δδ= δS−δR 
1 4.686 
4.596 
4.585 
4.385 
+0.101 
+0.211 
6 2.721 
2.496 
2.775 
2.649 
−0.054 
−0.153 
8 3.548 3.678 −0.130 
9 3.040 3.156 −0.116 
10 1.676 1.543 +0.133 
The differences in chemical shifts indicate the absolute configuration of S at the C-5 
carbinol. 
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(4R,6S)-4-[(R)-But-3-en-2-yl]-6-[(E)-4-(4-methoxybenzyloxy)but-2-en-2-yl]-2,2-dimethyl-
1,3-dioxane (102): To a stirred solution of the diol (24.8 mg, 0.0770 mmol, 1.0 equiv) in 1 mL 
of CH2Cl2 was added 0.10 mL of 2,2-dimethoxypropane (0.77 mmol, 10.0 equiv) followed by 
17.9 mg of (1R)-(−)-10-camphorsulfonic acid (0.0770 mmol, 1.0 equiv).  The reaction was 
stirred at ambient temperature for 24h.  The reaction was quenched by saturated NaHCO3 
aqueous solution and the aqueous phase was extracted three times with CH2Cl2.  The combined 
organic extracts were dried over anhydrous Na2SO4, filtered and concentrated.  The crude 
product was purified via flash chromatography on silica gel eluting with 7% EtOAc in hexanes 
to afford 15.1 mg of the title compound (54%) as clear oil.  
1
H NMR (500 MHz, CDCl3): δ 7.27 
(d, J= 8.5 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 5.73 (ddd, J= 18.0, 10.5, 8.0 Hz, 1H), 5.68 (t, J= 6.5 
Hz, 1H), 5.05 (d, J= 17.5 Hz, 1H), 5.02 (d, J= 10.5 Hz, 1H), 4.45 (s, 2H), 4.20 (H2) (dd, J= 11.5, 
1.5 Hz, 1H), 4.05 (d, J= 6.0 Hz, 2H), 3.81 (s, 3H), 3.62 (H1) (ddd, J= 11.0, 7.0, 2.0 Hz, 1H), 2.20 
(sextet, J= 7.0 Hz, 1H), 1.65 (s, 3H), 1.53 (dt, J= 12.5, 2.0 Hz, 1H), 1.45 (s, 3H), 1.43 (s, 3H), 
1.30 (q, J= 12.0 Hz, 1H), 1.05 (d, J= 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 159.2, 140.1, 
139.2, 130.5, 129.4, 122.5, 115.1, 113.8, 98.6, 73.8, 72.4, 72.1, 66.3, 55.3, 43.4, 33.1, 30.2, 19.8, 
15.8, 12.8.  NOESY spectrum of 102 showed a strong signal between H1 and H2, therefore the 
stereochemistry of the diol is syn.  In addition, based on Rychnovsky’s 13C NMR analysis, 
chemical shifts of 102 are consistent with the pattern characterized by syn diol compounds.
71a,b 
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6.0  EXPERIMENTAL FOR KETENE ENOLATE ALPHA-HYDROXYLATION 
General Information: Unless otherwise indicated, all reactions were performed in flame-dired 
glassware under an atmosphere of oxygen-free nitrogen using standard inert atmosphere 
techniques for the manipulation of both solvents and reagents.  Anhydrous solvents (CH2Cl2, 
THF, diethyl ether) were obtained by passage through successive alumina- and Q5-packed 
columns on a solvent purification system.  N,N-Diisopropylethylamine was distilled under 
nitrogen from CaH2.  O-Trimethylsilylquinidine (TMS-Qd) and O-trimethylsilylquinine (TMS-
Qn) were prepared according to the literature procedure.
66
  Commercially available propionyl 
chloride, butyryl chloride, valeryl chloride, and phenylacetyl chloride were distilled under N2.  
Commercially available 4-methoxyphenylacetyl chloride, 1-naphthaleneacetyl chloride, 2-
thiopheneacetyl chloride and 4-fluorophenylacetyl chloride were directly used without 
purification.  Other acid chlorides were made from the corresponding acid and purified before 
use.  Racemic N-p-nosyl oxaziridine was prepared according to the literature procedure.
62
 NMR 
Spectra were recorded at the indicated magnetic field strengths with chemical shifts reported 
relative to residual CHCl3 (7.27 ppm) for 
1
H and CDCl3 (77.0 ppm) for 
13
C spectra or residual 
CH2Cl2 (5.32 ppm) for 
1
H and CD2Cl2 (53.8 ppm) for 
13
C.  Analytical thin layer chromatography 
(TLC) was performed on 0.25 mm silica gel 60-F plates.  Flash chromatography was performed 
over silica gel (230-240 mesh).  Analytical gas chromatography (GC) was performed using a 
flame ionization detector and split mode capillary injection system using Varian Chirasil-Dex 
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CB WCOT fused silica 25 m x 0.25 mm column (CP 7502). Analytical high performance liquid 
chromatography (HPLC) was performed on a Hewlett Packard 1100 liquid chromatograph 
equipped with a variable wavelength UV detector (deuterium lamp, 190-600 nm) using a Daicel 
ChiracelTM OD-H column (250 x 4.6 mm) (Daicel Inc).  The concentration of the solution for 
optical rotations was in the unit of g 100 mL
-1
.   
 
 
 
 
 
General Procedure A.  Catalytic Asymmetric Ketene-Oxaziridine Cyclocondensation: To a 
solution of O-trimethylsilylquinine (TMSQn) or O-trimethylsilylquinidine (TMSQd) in CH2Cl2 
was added N,N-diisopropylethylamine (2 equiv, 0.5 M).  The resulting solution was cooled to 
−78 °C and stirred.  The oxaziridine (1 equiv) and the acid chloride (2 equiv) were combined and 
dissolved in CH2Cl2 (0.3 M for the oxaziridine) in a separate flask and the resulting 
homogeneous mixture was then transferred into the previously made −78 °C solution  via syringe 
pump over 2h.  Full consumption of the oxaziridine would be observed by TLC once the addition 
was complete.  The reaction was stirred for another 0.5 h and quenched at the same temperature 
by adding 10 mL of Et2O and slurry usually formed.  The heterogeneous mixture was then 
filtered through a short pad of silica, eluting with 40 mL of Et2O.  The filtrate was concentrated 
and the crude material was purified by flash column chromatography.   
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Enantiomeric excess determination: The enantiomeric excess was determined by chiral HPLC.  
The racemic samples were prepared by mixing products generated from utilizing TMSQn or 
TMSQd as the catalysts for the cyclocondensation.  In some cases when four isomers (two 
enantiomers of each diastereomer) were not completely separated on HPLC, employing single 
diastereomers to determine the ee was necessary.   
 
Stereochemistry assignment: The absolute stereochemistry at C5 of the oxazolidinones was 
assigned by comparison of the optical rotation of the ring opened compound [(S)-methyl 
mandelate 177] to the literature value.
67
 As for the relative stereochemistry of C2 and C5, we 
tentatively assigned the syn diastereomers as the ones that eluted first on column 
chromatography and the anti compounds as the ones that eluted last.  2D-NOESY analysis of 
173a further confirmed this assignment, as the syn isomer of 173a showed a strong signal 
between the C2 proton and the C5 proton.  The chemical shifts of the syn compounds were more 
down field in 
1
H NMR among all the oxazolidinones.  Further, all syn isomers have a negative 
optical rotation and anti ones have a positive optical rotation. 
 
 (5S)-5-Methyl-3-[(4-nitrophenyl)sulfonyl]-2-
phenyloxazolidin-4-one (173e): General procedure A was 
followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn 
(0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 
52.1 µL of propionyl chloride (0.600 mmol, 2 equiv).  The crude products were purified via flash 
chromatography (6% to 13% EtOAc in hexanes) to yield 81 mg (74%) of the compound as a 
mixture of two diastereomers.  Effective separation of these two diastereomers could be achieved 
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by using MPLC for characterization purpose. Full characterization of the syn compound: [] 19D
−43.3 (c 2.40, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.22 (d, J= 9.2 Hz, 2H), 7.79 (d, J= 8.8 
Hz, 2H), 7.46 (t, J= 7.2, Hz, 1H), 7.39-7.34 (m, 2H), 7.29-7.27 (m, 2H), 6.57 (d, J= 0.8 Hz, 1H), 
4.62 (dq, J = 0.8, 6.8 Hz, 1H), 1.50 (d, J= 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  170.9, 
150.8, 143.0, 136.1, 130.4, 129.5, 128.8, 127.2, 123.9, 90.7, 73.8, 17.0; IR max
 
cm
-1
:2959, 2925, 
2854, 1756, 1534, 1460, 1380, 1350, 1315, 1232, 1181, 1109, 1087, 1059, 760, 741; HRMS 
(ES+) m/z calcd for C16H14N2O6NaS (M+Na)
+
: 385.0470; found: 385.0474.  Full characterization 
of the anti compound: [] 19D  +49.5 (c 1.90, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.18 (d, J= 
8.8 Hz, 2H), 7.62 (d, J= 8.8 Hz, 2H), 7.48 (t, J= 7.2 Hz, 1H), 7.38-7.29 (m, 4H), 6.45 (d, J= 0.8 
Hz, 1H), 4.58 (dq, J= 0.8, 6.8 Hz, 1H), 1.52 (d, J= 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ 
170.5, 150.7, 143.5, 135.3, 130.7, 129.1, 128.5, 128.4, 123.9, 90.6, 74.3, 16.8; ; IR max
 
cm
-1
: 
1747, 1533, 1384, 1351, 1315, 1292, 1219, 1202, 1181, 1089, 1056, 856, 741; HRMS (ES+) m/z 
calcd for C16H14N2O6NaS (M+Na)
+
: 385.0470; found: 385.0439.  The ee (>98%) was determined 
by chiral HPLC employing the syn diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 
1.0 mL/min, 15% 
i
PrOH/85% hexanes, Tr: 17.3 min (2R, 5S), 23.0 min (2S, 5R).   
 
(5S)-5-Ethyl-3-[(4-nitrophenyl)sulfonyl]-2-
phenyloxazolidin-4-one (173f): General procedure A was 
followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn 
(0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 
62.3 µL of butyryl chloride (0.600 mmol, 2 equiv).  The crude product was purified via flash 
chromatography (6% to 12% EtOAc in hexanes) to yield 80 mg (71%) of the compound as a 
mixture of two diastereomers.  Effective separation of these two diastereomers could be achieved 
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by using MPLC for characterization purpose.  Full characterization of the syn compound: [] 19D
−69.0 (c 1.00, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 8.8 Hz, 2H), 7.77 (d, J= 9.2 
Hz, 2H), 7.46 (t, J= 7.2 Hz, 1H), 7.38-7.34 (m, 2H), 7.30-7.27 (m, 2H), 6.57 (d, J= 1.2 Hz, 1H), 
4.51 (ddd, J= 1.2, 4.8, 6.4 Hz, 1H), 1.99-1.78 (m, 2H), 1.02 (t, J= 7.2 Hz, 3H); 
 13
C NMR (100 
MHz, CDCl3):  170.4, 150.8, 143.1, 136.4, 130.4, 129.4, 128.8, 127.2, 123.9, 91.2, 78.4, 25.1, 
8.6; IR max
 
cm
-1
: 1756, 1534, 1382, 1351, 1316, 1230, 1181, 1089, 856, 742; HRMS (ES+) m/z 
calcd for C17H16N2O6NaS (M+Na)
+
: 399.0627; found: 399.0661.  Full characterization of the anti 
compound: [] 19D  +35.8 (c 1.09, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.19 (d, J= 9.2 Hz, 2H), 
7.65 (d, J= 9.2 Hz, 2H), 7.48 (t, J= 7.2 Hz, 1H), 7.38-7.30 (m, 4H), 6.43 (d, J= 1.2Hz, 1H), 4.42 
(ddd, J = 1.2, 4.4, 6.8 Hz, 1H),  2.05-1.94 (m, 1H), 1.82 (dquintet, J= 14.4, 7.2 Hz, 1H), 1.04 (t, 
J= 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  170.0, 150.7, 143.7, 135.4, 130.7, 129.1, 128.5, 
128.4, 123.9, 90.6, 78.7, 24.4, 9.2; IR max: 1757, 1534, 1373, 1355, 1312, 1218, 1177, 1110, 
1089, 741; HRMS (ES+) m/z calcd for C17H16N2O6NaS (M + Na)
+
: 399.0627; found: 399.0647.  
The ee (>98%) was determined by chiral HPLC employing the the mixture of syn and anti 
diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 mL/min, 7% EtOH/93% hexanes, 
Tr: 15.6 min (2R, 5S), 19.2 min (2S, 5R), 25.0 min (2S, 5S), 27.3 min (2R, 5R). 
 
(5S)-3-[(4-Nitrophenyl)sulfonyl]-2-phenyl-5-
propyloxazolidin-4-one (173g): General procedure A 
was followed employing 91.8 mg of N-nosyl 
oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 mmol, 20 mol %), 0.11 mL of 
N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 72.7 µL of valeryl chloride (0.60 mmol, 2 
equiv).  The crude product was purified via flash chromatography (6% to 9% EtOAc in hexanes) 
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to yield 88 mg (75%) of the compound as a mixture of two diastereomers.  Effective separation 
of these two diastereomers could be achieved by using MPLC for characterization purpose. Full 
characterization of the syn compound: [] 19D −69.9 (c 1.03, CHCl3);
1
H NMR (400 MHz, CDCl3): 
 8.20 (d, J= 8.8 Hz, 2H), 7.75 (d, J= 9.2 Hz, 2H), 7.46 (t, J= 7.6 Hz, 1H), 7.38-7.34 (m, 2H), 
7.29-7.26 (m, 2H), 6.56 (d, J= 1.2 Hz, 1H), 4.55 (ddd, J= 1.2, 4.4, 7.2 Hz, 1H), 1.90-1.73 (m, 
2H), 1.54-1.40 (m, 2H), 0.95 (t, J= 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  170.5, 150.8, 
143.1, 136.3, 130.4, 129.4, 128.8, 127.3, 123.9, 91.1, 77.3, 33.6, 17.8, 13.6; IR max
 
cm
-1
: 1756, 
1534, 1383, 1350, 1314, 1181, 1108, 1088, 740; HRMS (ASAP) m/z calcd for C18H17N2O6S (M-
H)
-
: 389.0809; found: 389.0815; Full characterization of the anti compound: [] 19D  +34.9 (c 1.06, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.18 (d, J= 8.8 Hz, 2H), 7.64 (d, J= 9.2 Hz, 2H), 7.48 (t, 
J= 7.2 Hz, 1H), 7.38-7.29 (m, 4H), 6.43 (d, J= 1.2 Hz, 1H), 4.47 (ddd, J= 1.2, 4.0, 7.6 Hz, 1H), 
1.96-1.89 (m, 1H), 1.79-1.70 (m, 1H), 1.53-1.44 (m, 2H), 0.94 (t, J= 7.6 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3):  170.2, 150.7, 143.6, 135.4, 130.7, 129.1, 128.5, 128.4, 123.9, 90.7, 77.6, 33.2, 
18.2, 13.6; IR max
 
cm
-1
: 1757, 1534, 1383, 1350, 1313, 1217, 1182, 1089, 740; HRMS (ES+) 
m/z calcd for C18H18N2O6NaS (M+Na)
+
: 413.0783; found: 413.0811.  The ee (>98%) was 
determined by chiral HPLC employing the syn diastereomers.  Daicel Chiracel
TM
 OD-H column, 
flow rate 1.0 mL/min, 7% EtOH/93% hexanes, Tr: 12.4 min (2R, 5S), 14.3 min (2S, 5R). 
 
 (5S)-5-(Cyclohexylmethyl)-3-[(4-
nitrophenyl)sulfonyl]-2-phenyloxazolidin-4-one 
(173h): General procedure A was followed employing 
91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 mmol, 20 
mol%), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 105 mg of 3-
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cyclohexylpropanoyl chloride (0.600 mmol, 2 equiv).  The crude product was purified via flash 
chromatography (6% to 9% EtOAc in hexanes) to yield 100 mg (75%) of the compound as a 
mixture of two diastereomers.  Effective separation of these two diastereomers could be achieved 
by using MPLC for characterization purpose. Full characterization of the syn compound: [] 18D
−63.9 (c 2.85, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 9.2 Hz, 2H), 7.76 (d, J= 8.8 
Hz, 2H), 7.46 (t, J= 7.2 Hz, 1H), 7.38-7.34 (m, 2H), 7.29-7.27 (m, 2H), 6.55 (d, J= 0.8 Hz, 1H), 
4.60 (ddd, J= 0.8, 4.4, 8.8 Hz, 1H), 1.77-1.62 (m, 7H), 1.57-1.50 (m, 1H), 1.27-1.11 (m, 3H), 
1.01-0.89 (m, 2H); 
13
C NMR (100 MHz, CDCl3):  171.0, 150.8, 143.1, 136.3, 130.4, 129.4, 
128.8, 127.3, 123.9, 90.8, 75.8, 38.9, 33.8, 33.6, 32.3, 26.2, 26.1, 25.9; IR max
 
cm
-1
: 2925, 2851, 
1756, 1534, 1383, 1350, 1317, 1230, 1181, 1108, 1089, 856, 758, 742; HRMS (ES+) m/z calcd 
for C22H24N2O6NaS (M+Na)
+
: 467.1253; found: 467.1263.  Full characterization of the anti 
compound: [] 19D  0 (c 1.06, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.18 (d, J= 8.8 Hz, 2H), 7.63 
(d, J= 8.8 Hz, 2H), 7.48 (t, J= 7.2 Hz, 1H), 7.38-7.30 (m, 4H), 6.43 (d, J= 1.2 Hz), 4.53 (ddd, J= 
1.2, 3.6, 9.6 Hz), 1.86-1.80 (m, 1H), 1.79-1.76 (m, 1H), 1.71-1.60 (m, 6H), 1.26-1.08 (m, 3H), 
1.00-0.87 (m, 2H); 
13
C NMR (100 MHz, CDCl3):  170.7, 150.7, 143.6, 135.4, 130.6, 129.1, 
128.5, 123.9, 90.7, 76.0, 39.0, 33.9, 33.7, 32.2, 26.2, 26.0, 25.9; IR max
 
cm
-1
: 2925, 2851, 1756, 
1533, 1383, 1350, 1316, 1220, 1182, 1089, 741; HRMS (ES+) m/z calcd for C22H24N2O6NaS (M 
+ Na)
+
: 467.1253; found: 467.1253.  The ee (>98%) was determined by chiral HPLC employing 
the the mixture of syn and anti diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 
ml/min, 5% EtOH/95% hexanes, Tr: 11.7 min (2R, 5S), 14.1 min (2S, 5R), 19.2 min (2R, 5R), 
22.3 min (2S, 5S). 
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(5S)-3-[(4-Nitrophenyl)sulfonyl]-2,5-
diphenyloxazolidin-4-one (173a): General procedure A 
was followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of 
TMSQn (0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 
equiv), and 79.5 µL of phenylacetyl chloride (0.600 mmol, 2 equiv).  The crude product was 
purified via flash chromatography (6% to 13% EtOAc in hexanes) to yield 100 mg (79%) of the 
compound as a mixture of two diastereomers.  Effective separation of these two diastereomers 
could be achieved by using MPLC for characterization purpose. Full characterization of the syn 
compound: [] 19D −96.4 (c 1.11, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.19 (d, J= 9.2 Hz, 2H), 
7.75 (d, J= 9.2 Hz, 2H), 7.50 (t, J= 6.8 Hz, 1H), 7.46-7.36 (m, 9H), 6.73 (d, J= 1.2 Hz, 1H), 5.52 
(d, J= 0.8 Hz, 1H);  13C NMR (100 MHz, CDCl3):  168.6, 150.8, 142.9, 135.9, 133.7, 130.7, 
129.5, 129.4, 129.0, 128.9, 127.6, 126.1, 123.9, 91.3, 78.7; IR max
 
cm
-1
: 1757, 1533, 1384, 1350, 
1230, 1181, 756, 741; HRMS (ES+) m/z calcd for C21H16N2O6NaS (M + Na)
+
: 447.0627; found: 
447.0625.  Full characterization of the anti compound: [] 19D  +78.2 (c 1.01, CHCl3); 
1
H NMR 
(400 MHz, CDCl3):  8.17 (d, J= 9.2 Hz, 2H), 7.67 (d, J= 9.2 Hz, 2H), 7.54-7.49 (m, 1H), 7.44-
7.35 (m, 9H), 6.64 (d, J= 1.2 Hz, 1H), 5.50 (d, J= 0.8 Hz, 1H);  13C NMR (100 MHz, CDCl3):  
168.4, 150.7, 143.3, 135.4, 133.2, 130.8, 129.3, 129.1, 128.7, 128.6, 128.5, 126.2, 124.0, 90.7, 
78.8; IR max
 
cm
-1
: 1760, 1533, 1384, 1350, 1318, 1219, 1182, 1088, 742; HRMS (ES+) m/z 
calcd for C21H16N2O6NaS (M+Na)
+
: 447.0627; found: 447.0585.  The ee (>98%) was determined 
by chiral HPLC employing the syn diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 
1.0 ml/min, 25% 
i
PrOH/975% hexanes, Tr: 21.2 min (2S, 5R), 50.1 min (2R, 5S).  
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(5S)-5-(4-Methoxyphenyl)-3-[(4-
nitrophenyl)sulfonyl]-2-phenyloxazolidin-4-one 
(173b): General procedure A was followed 
employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 
mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 91.8 µL of 
4-methoxyphenylacetyl chloride (0.600 mmol, 2 equiv).  The crude product was purified via 
flash chromatography (6% to 15% EtOAc in hexanes) to yield 107 mg (79%) of the compound 
as a mixture of two diastereomers.  Effective separation of these two diastereomers could be 
achieved by using MPLC for characterization purpose. Full characterization of the syn 
compound: [] 19D −82.9 (c 1.05, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 9.2 Hz, 2H), 
7.76 (d, J= 9.2 Hz, 2H), 7.49 (t, J= 6.8 Hz, 1H), 7.42-7.31 (m, 6H), 6.94 (d, J= 8.8 Hz, 2H), 6.70 
(d, J= 1.2 Hz, 1H), 5.46 (s, 1H), 3.83 (s, 3H);  13C NMR (100 MHz, CDCl3):  168.9, 160.5, 
150.8, 143.0, 135.9, 130.6, 129.5, 128.9, 127.8, 127.5, 125.7, 123.9, 114.5. 91.1, 78.6, 55.4; IR 
max
 
cm
-1
: 1757, 1610, 1534, 1514, 1383, 1350, 1316, 1230, 1179, 1113, 1087, 741; HRMS 
(ES+) m/z calcd for C22H18N2O7NaS (M+Na)
+
: 477.0732; found: 477.0782; Full characterization 
of the anti compound: [] 17D  +91.5 (c 1.36, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.17 (d, J= 
8.8 Hz, 2H), 7.67 (d, J= 9.2 Hz, 2H), 7.50 (t, J= 6.4 Hz, 1H), 7.40-7.31 (m, 6H), 6.91 (d, J= 8.8 
Hz, 2H), 6.60 (d, J= 1.6 Hz, 1H), 5.44 (s, 1H), 3.80 (s, 3H);  13C NMR (100 MHz, CDCl3):  
168.7, 160.3, 150.7, 143.4, 135.4, 130.8, 129.3, 128.6, 128.5, 127.9, 125.3, 124.0, 114.2, 90.5, 
78.9, 55.3; IR max
 
cm
-1
: 1758, 1611, 1534, 1516, 1461, 1383, 1350, 1317, 1252, 1219, 1180, 
1088, 1029, 856, 742; HRMS (ES+) m/z calcd for C22H18N2O7NaS (M+Na)
+
: 477.0732; found: 
477.0762.  The ee (>98%) was determined by chiral HPLC employing the syn diastereomers.  
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Daicel Chiracel
TM
 OD-H column, flow rate 1.0 mL/min, 20% 
i
PrOH/80% hexanes, Tr: 38.7 min 
(2S, 5R), 89.7 min (2R, 5S).  
 
(5S)-5-(4-Fluorophenyl)-3-((4-
nitrophenyl)sulfonyl)-2-phenyloxazolidin-4-one 
(173c): General procedure A was followed 
employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 
mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 82.3 µL of 
4-fluorophenylacetyl chloride (0.6 mmol, 2 equiv).  The crude product was purified via flash 
chromatography (6% to 14% EtOAc in hexanes) to yield 101 mg (76%) of the compound as a 
mixture of two diastereomers.  Effective separation of these two diastereomers could be achieved 
by using MPLC for characterization purpose. Full characterization of the syn compound: [] 19D
−68.3 (c 1.04, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 9.2 Hz, 2H), 7.74 (d, J= 9.2 
Hz, 2H), 7.51 (t, J= 7.2 Hz, 1H), 7.45-7.34(m, 6H), 7.13 (t, J= 8.8 Hz, 2H), 6.73 (d, J= 1.2 Hz, 
1H), 5.50 (s, 1H);  13C NMR (100 MHz, CDCl3):  168.4, 150.9, 142.8, 135.7, 130,7, 129.6, 
129.5, 128.9, 128.1, 128.0, 127.5, 123.9, 116.2, 116.0, 91.3, 78.1; IR max
 
cm
-1
: 1758, 1534, 
1511, 1384, 1350, 1316, 1229, 1182, 1159, 1111, 1088, 760, 741; HRMS (ASAP with APCI) 
m/z cald for C21H14N2O6FS (M-H)
+
: 441.0557; found: 441.0559; Full characterization of the anti 
compound: [] 19D  +59 (c 0.44, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.18 (d, J= 9.2 Hz, 2H), 
7.67 (d, J= 8.8 Hz, 2H), 7.52 (t, J= 7.2 Hz, 1H), 7.43-7.37 (m, 4H), 7.35-7.32 (m, 2H), 7.08 (appt 
t, J= 8.8 Hz, 2H), 6.63 (d, J= 1.6 Hz, 1H), 5.48 (s, 1H);  13C NMR (75 MHz, CDCl3):  168.2, 
150.8, 143.2, 135.3, 130.9, 129.3, 128.7, 128.4, 128.1, 128.0, 124.0, 115.9, 115.7, 90.7, 78.3; IR 
max
 
cm
-1
: 1759, 1534, 1512, 1385, 1350, 1316, 1223, 1183, 1159, 1088, 742; HRMS (ES+) m/z 
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calcd for C21H15N2O6FNaS (M+Na)
+
: 465.0533; found: 465.0538; The ee (>98%) was 
determined by chiral HPLC employing the anti diastereomers.  Daicel Chiracel
TM
 OD-H column, 
flow rate 1.0 ml/min, 20% 
i
PrOH/80% hexanes, Tr: 29.3 min (2R, 5S), 37.1 min (2S, 5R). 
 
 
 (5S)-5-(Naphthalen-1-yl)-3-[(4-
nitrophenyl)sulfonyl]-2-phenyloxazolidin-4-one  
(173d): General procedure A was followed employing 
91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 mmol, 20 
mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 123 mg of 1-
naphthaleneacetyl chloride (0.600 mmol, 2 equiv).  The crude product was purified via flash 
chromatography (6% to 14% EtOAc in hexanes) to yield 113 mg (80%) of the compound as a 
mixture of two diastereomers.  Effective separation of these two diastereomers could be achieved 
by using MPLC for characterization purpose. Full characterization of the syn compound: [] 19D
−25.5 (c 1.37, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.22 (d, J= 8.8 Hz, 2H), 7.99-7.97 (m, 
1H), 7.93-7.89 (m, 2H), 7.81 (d, J= 8.8 Hz, 2H), 7.61-7.79 (m, 1H), 7.56-7.49 (m, 4H), 7.46- 
7.42 (m, 4H), 6.76 (d, J=0.8 Hz, 1H), 6.23 (s, 1H);  13C NMR (100 MHz, CDCl3):  168.7, 
150.9, 143.0, 135.8, 134.0, 131.0, 130.7, 130.5, 129.6, 129.3, 128.92, 128.87, 127.7, 126.9, 
126.3, 125.1, 124.9, 124.0, 123.3, 91.1, 77.2; IR max
 
cm
-1
: 1757, 1533, 1382, 1350, 1315, 1228, 
1181, 1089, 741; HRMS (ES+) m/z calcd for C25H18N2O6NaS (M+Na)
+
: 497.0783; found: 
497.0795; Full characterization of the anti compound: [] 19D  +140 (c 0.55, CHCl3); 
1
H NMR 
(400 MHz, CDCl3):  8.17 (d, J= 8.8 Hz, 2H), 8.06 (d, J= 8.0 Hz, 1H), 7.91-7.87 (m, 2H), 7.69 
(d, J= 9.2 Hz, 2H), 7.60-7.50 (m, 4H), 7.46-7.38 (m, 5H), 6.75 (d, J= 1.6 Hz, 1H), 6.32 (s, 1H);  
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13
C NMR (100 MHz, CDCl3):  168.3, 150.8, 143.3, 135.3, 133.8, 130.9, 130.0, 129.3, 129.1, 
128.8, 128.7, 128.6, 126.8, 126.3, 125.1, 124.3, 124.0, 123.5, 90.8, 76.9; IR max
 
cm
-1
: 1759, 
1533, 1383, 1350, 1219, 1182, 1088, 760, 741; HRMS (ES+) m/z calcd for C25H18N2O6NaS (M + 
Na)
+
: 497.0783; found: 497.0803.  The ee (>98%) was determined by chiral HPLC employing 
the syn diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 ml/min, 20% 
i
PrOH/80% 
hexanes, Tr: 30.0 min (2R, 5S), 33.0 min (2S, 5R). 
 
 (5R)-3-[(4-Nitrophenyl)sulfonyl]-2-phenyl-5-
(thiophen-2-yl)oxazolidin-4-one (173k): General 
procedure A was followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 
24.0 mg of TMSQn (0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 
mmol, 2 equiv), and 96.4 mg of 2-thiopheneacetyl chloride (0.600 mmol, 2 equiv).  The crude 
product was purified via flash chromatography (6% to 14% EtOAc in hexanes) to yield 91 mg 
(70%) of the compound as a mixture of two diastereomers.  Effective separation of these two 
diastereomers could be achieved by using MPLC for characterization purpose. Full 
characterization of the syn compound: [] 19D −80.7 (c 1.50, CHCl3); 
1
H NMR (400 MHz, CDCl3): 
 8.22 (d, J= 8.8 Hz, 2H), 7.79 (d, J= 8.8 Hz, 2H), 7.50 (t, J= 6.8 Hz, 1H), 7.43-7.36 (m, 5H), 
7.17 (d, J= 3.6 Hz, 1H), 7.06 (dd, J= 3.6, 5.2 Hz, 1H), 6.69 (d, J= 0.8 Hz, 1H), 5.73 (t, J= 0.8 Hz, 
1H);  13C NMR (100 MHz, CDCl3):  167.5, 150.9, 142.8, 135.7, 135.4, 130.7, 129.5, 128.9, 
127.6, 127.43, 127.38, 126.9, 124.0, 91.1, 75.5; IR max
 
cm
-1
: 1759, 1533, 1404, 1383, 1350, 
1316, 1227, 1183, 1087, 741; Satisfactory HRMS data was not obtained; Full characterization of 
the anti compound: [] 18D  +16.4 (c 1.22, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.17 (d, J= 9.2 
Hz, 2H), 7.65 (d, J= 9.2 Hz, 2H), 7.52-7.48 (m, 1H), 7.38-7.36 (m, 5H), 7.19 (d, J= 3.6 Hz, 1H), 
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7.04 (dd, J= 3.6, 5.2 Hz, 1H), 6.60 (d, J= 1.6 Hz, 1H), 5.75 (t, J= 1.2 Hz, 1H);  13C NMR (100 
MHz, CDCl3):  167.2, 150.8, 143.2, 135.6, 135.0, 130.9, 129.2, 128.6, 127.2, 127.1, 124.0, 
90.8, 76.1; IR max
 
cm
-1
: 1761, 1533, 1384, 1350, 1219, 1183, 1088, 740; Satisfactory HRMS 
data was not obtained; The ee (>98%) was determined by chiral HPLC employing the the 
mixture of syn and anti diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 ml/min, 
20% EtOH /80% hexanes, Tr: 16.7 min (2S, 5R), 26.5 min (2R, 5R), 51.8 min (2R, 5S), 62.4 min 
(2S, 5S). 
  
 2-{[(5S)-3-(4-Nitrophenylsulfonyl)-4-oxo-
2-phenyloxazolidin-5-yl]methyl}isoindoline-1,3-
dione (173m): General procedure A was followed 
employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 
mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 143 mg of 
1-(2-phthalimidopropionyl) chloride (0.600 mmol, 2 equiv).  The crude product was purified via 
flash chromatography (6% to 30% EtOAc in hexanes) to yield 89 mg (59%) of the compound as 
a mixture of two diastereomers.  Effective separation of these two diastereomers could be 
achieved by using MPLC for characterization purpose. Full characterization of the syn 
compound: [] 18D  −53.1 (c 1.60, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 8.8 Hz, 2H), 
7.87-7.81 (m, 2H), 7.77-7.71 (m, 4H), 7.44 (t, J= 7.2 Hz, 1H), 7.36-7.30 (m, 2H), 7.28-7.26 (m, 
2H), 6.62 (d, J= 0.8 Hz, 1H), 4.92 (ddd, J= 1.2, 5.2, 8.4 Hz, 1H), 4.18-4.06 (m, 2H);  13C NMR 
(100 MHz, CDCl3):  167.6, 167.5, 150.9, 142.8, 135.5, 134.3, 131.7, 130.6, 129.5, 128.8, 127.5, 
124.0, 123.6, 91.3, 74.2, 38.2; IR max
 
cm
-1
: 1759, 1718, 1534, 1463, 1424, 1385, 1350, 1319, 
1270, 1231, 1183, 1089, 1000, 859, 739; HRMS (ES+) m/z calcd for C24H17N3O8NaS (M + Na)
+
: 
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530.0634; found: 530.0604.  Full characterization of the anti compound: [] 15D  −50 (c 0.56, 
CH2Cl2); 
1
H NMR (400 MHz, CDCl3):  8.20 (d, J= 9.2 Hz, 2H), 7.82 (dd, J= 2.8, 5.6 Hz, 2H), 
7.72 (dd, J= 3.2, 5.6 Hz, 2H), 7.63 (d, J= 8.8 Hz, 2H), 7.46-7.42 (m, 1H), 7.31-7.30 (m, 4H), 
6.44 (d, J= 1.2 Hz, 1H), 4.94 (dt, J= 1.2, 6.8 Hz, 1H), 4.15 (d, J= 6.8 Hz, 2H); 
13
C NMR (100 
MHz, CD2Cl2):  168.2, 167.9, 151.2, 143.6, 135.2, 134.6, 132.1, 131.1, 129.5, 128.8, 128.7, 
124.4, 123.7, 91.6, 74.4, 38.7; IR max
 
cm
-1
: 1759, 1718, 1532, 1384, 1350, 1225, 1182, 1088, 
740, 720; HRMS (ES+) m/z calcd for C24H17N3O8NaS (M + Na)
+
: 530.0634; found: 530.0637.  
The ee (>98%) was determined by chiral HPLC employing the the mixture of syn and anti 
diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 ml/min, 35% 
i
PrOH /65% 
hexanes, Tr: 34.1 min (2R, 5S), 41.2 min (2S, 5R), 49.8 min (2S, 5S), 75.2 min (2R, 5R). 
 
 (5S)-3-[(4-Nitrophenyl)sulfonyl]-5-
(phenoxymethyl)-2-phenyloxazolidin-4-one 
(173j): General procedure A was followed employing 91.8 mg of N-nosyl oxaziridine (0.300 
mmol, 1 equiv), 24.0 mg of TMSQn (0.0600 mmol, 20 mol %), 0.11 mL of N,N-
diisopropylethylamine (0.60 mmol, 2 equiv), and 111 mg of 3-phenoxypropanoyl chloride (0.600 
mmol, 2 equiv).  The crude product was purified via flash chromatography (6% to 20% EtOAc in 
hexanes) to yield 111 mg (82%) of the compound as a mixture of two diastereomers.  Effective 
separation of these two diastereomers could be achieved by using MPLC for characterization 
purpose. Full characterization of the syn compound: [] 18D  −80.5 (c 1.18, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  8.19 (d, J= 8.8 Hz, 2H), 7.87 (d, J= 9.2 Hz, 2H), 7.50-7.47 (m, 1H), 7.42-7.41 
(m, 4H), 7.30-7.26 (m, 2H), 7.01 (t, J= 7.2 Hz, 1H), 6.81 (d, J= 8.0 Hz, 2H), 6.68 (d, J= 0.8 Hz, 
1H), 4.82 (d, J= 1.2 Hz, 1H), 4.35 (d, J= 1.6 Hz, 2H);  13C NMR (100 MHz, CDCl3):  168.6, 
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157.7, 150.8, 143.0, 136.6, 130.6, 129.6, 129.5, 128.8, 127.5, 124.0, 122.1, 115.0, 92.7, 77.2, 
68.5; IR max
 
cm
-1
: 1758, 1600, 1533, 1495, 1458, 1403, 1383, 1350, 1315, 1228, 1182, 1108, 
1088, 1063, 1037, 856, 739; HRMS (ES+) m/z calcd for C22H18N2O7NaS (M + Na)
+
: 477.0732; 
found: 477.0761.  Full characterization of the anti compound: [] 18D  +72.1 (c 1.04, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  8.17 (d, J= 8.8 Hz, 2H), 7.63 (d, J= 8.8 Hz, 2H), 7.52-7.51 (m, 2H), 
7.46 (t, J= 7.2 Hz, 1H), 7.34-7.25 (m, 4H), 6.99 (t, J= 7.2 Hz, 1H), 6.76 (d, J= 8.0 Hz, 2H), 6.56 
(d, J= 0.8 Hz, 1H), 4.87 (d, J= 1.2 Hz, 1H), 4.39-4.38 (m, 2H);  13C NMR (100 MHz, CDCl3):  
167.3, 157.8, 150.7, 143.6, 135.2, 130.7, 129.6, 129.0, 128.8, 128.3, 123.9, 121.8, 114.5, 91.0, 
77.1, 66.2; IR max
 
cm
-1
: 1760, 1533, 1496, 1384, 1350, 1313, 1222, 1182, 1088, 755, 741; 
HRMS (ES+) m/z calcd for C22H18N2O7NaS (M+Na)
+
: 477.0732; found: 477.0736.  The ee 
(>98%) was determined by chiral HPLC employing the syn diastereomers.  Daicel Chiracel
TM
 
OD-H column, flow rate 1.0 ml/min, 20% 
i
PrOH/80% hexanes, Tr: 45.8 min (2R, 5S), 51.0 min 
(2S, 5R). 
 
 (5S)-3-[(4-Nitrophenyl)sulfonyl]-2-
phenyl-5-[(E)-styryl]oxazolidin-4-one (173l): 
General procedure A was followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 
equiv), 24.0 mg of TMSQn (0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine 
(0.60 mmol, 2 equiv), and 108 mg of trans-styrylacetyl chloride (0.600 mmol, 2 equiv).  The 
crude product was purified via flash chromatography (6% to 13% EtOAc in hexanes) to yield 
86.4 mg (64%) of the compound as a mixture of two diastereomers.  Effective separation of these 
two diastereomers could be achieved by using MPLC for characterization purpose. Full 
characterization of the syn compound: [] 18D  −47 (c 0.87, CHCl3); 
1
H NMR (400 MHz, CDCl3):  
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8.21 (d, J= 8.8 Hz, 2H), 7.77 (d, J= 8.8 Hz, 2H), 7.49 (t, J= 7.2 Hz, 1H), 7.42-7.29 (m, 9H), 6.82 
(dd, J= 1.6, 16.0 Hz, 1H), 6.66 (d, J= 1.2 Hz, 1H), 6.21 (dd, J= 6.0, 16.0 Hz, 1H), 5.17 (dt, J= 
6.0, 1.2 Hz, 1 H);  13C NMR (100 MHz, CDCl3):  168.4, 150.8, 142.9, 135.8, 135.3, 135.1, 
130.6, 129.4, 128.84, 128.80, 128.7, 127.5, 126.9, 124.0, 120.3, 91.1, 78.1; IR max
 
cm
-1
: 2923, 
1756, 1533, 1383, 1350, 1315, 1225, 1182, 1109, 1088, 969, 740; HRMS (ASAP with APCI) 
m/z calcd for C23H19N2O6S (M+H)
+
: 451.0964; found: 451.0953. Full characterization of the anti 
compound: [] 18D  +31 (c 0.95, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.18 (d, J= 8.8 Hz, 2H), 
7.65 (d, J= 8.8 Hz, 2H), 7.50 (t, J= 6.8 Hz, 1H), 7.39-7.28 (m, 9H), 6.76 (dd, J= 1.2, 16.0 Hz, 
1H), 6.58 (d, J= 0.8 Hz, 1H), 6.22 (dd, J= 5.6, 16.0 Hz, 1H), 5.17 (dt, J= 5.6, 1.2 Hz, 1H);  13C 
NMR (100 MHz, CDCl3):  168.2, 150.8, 143.2, 135.6, 135.3, 135.2, 130.7, 129.3, 128.7, 128.6, 
128.4, 126.9, 124.0, 120.7, 90.9, 78.4; IR max
 
cm
-1
: 1757, 1533, 1383, 1350, 1315, 1219, 1183, 
1088, 740; HRMS (ASAP with APCI) m/z calcd for C23H19N2O6S (M+H)
+
: 451.0964; found: 
451.0963.  The ee (>98%) was determined by chiral HPLC employing the syn diastereomers.  
Daicel Chiracel
TM
 OD-H column, flow rate 1.0 ml/min, 20% 
i
PrOH/80% hexanes, Tr: 28.8 min 
(2R, 5S), 44.3 min (2S, 5R). 
 
 (5S)-5-Cyclopropyl-3-[(4-nitrophenyl)sulfonyl]-2-
phenyloxazolidin-4-one (173i): General procedure A was 
followed employing 91.8 mg of N-nosyl oxaziridine (0.300 mmol, 1 equiv), 24.0 mg of TMSQn 
(0.0600 mmol, 20 mol %), 0.11 mL of N,N-diisopropylethylamine (0.60 mmol, 2 equiv), and 
71.2 mg of cyclopropylacetyl chloride (0.600 mmol, 2 equiv).  The crude product was purified 
via flash chromatography (6% to 13% EtOAc in hexanes) to yield 82.0 mg (70%) of the 
compound as a mixture of two diastereomers.  Effective separation of these two diastereomers 
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could be achieved by using MPLC for characterization purpose. Full characterization of the syn 
compound: [] 19D −64.0 (c 1.11, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.19 (d, J= 8.8 Hz, 2H), 
7.75 (d, J= 8.8 Hz m, 2H), 7.45 (t, J= 8.8 Hz, 1H), 7.35 (t, J= 8.0 Hz, 2H), 7.26-7.24 (m, 2H), 
6.57 (d, J= 0.8 Hz, 1H), 4.11 (dd, J= 0.8, 7.2 Hz, 1H), 1.28-1.20 (m, 1H), 0.76-0.45 (m, 4H);  
13
C NMR (100 MHz, CDCl3):  169.5, 150.8, 143.0, 136.2, 130.4, 129.4, 128.8, 127.3, 123.9, 
91.0, 80.2, 12.3, 1.8, 1.6; IR max
 
cm
-1
: 1757, 1535, 1382, 1350, 1232, 1180, 741; HRMS (ASAP 
with APCI) m/z calcd for C18H15N2O6S (M-H)
+
 387.0651; found: 387.0647; Full characterization 
of the anti compound: [] 19D  +49.5 (c 1.11, CHCl3); 
1
H NMR (400 MHz, CDCl3):  8.19 (d, J= 
8.8 Hz, 2H), 7.67 (d, J= 8.8 Hz, 2H), 7.48 (t, J= 6.8 Hz, 1H), 7.38-7.31 (m, 4H), 6.41 (d, J= 1.2 
Hz, 1H), 3.94 (dd, J= 1.2, 7.6 Hz, 1H), 1.21-1.12 (m, 1H), 0.78-0.72 (m, 1H), 0.67-0.55 (m, 2H), 
0.54-0.46 (m, 1H);  13C NMR (100 MHz, CDCl3):  169.4, 150.7, 143.5, 135.5, 130.7, 129.2, 
128.6, 128.3, 124.0, 90.3, 81.3, 11.9, 2.1, 1.8; IR max
 
cm
-1
: 1759, 1534, 1402, 1381, 1351, 1317, 
1291, 1222, 1181, 1089, 1049, 1012, 859, 740; HRMS (ASAP with APCI) m/z calcd for 
C18H17N2O6S (M+H)
+
 389.0807; found: 389.0855; The ee (>98%) was determined by chiral 
HPLC employing the syn diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 
mL/min, 10% 
i
PrOH/90% hexanes, Tr: 21.1 min (2R, 5S), 24.7 min (2S, 5R). 
 
(5S)-5-Cyclohexyl-3-((4-nitrophenyl)sulfonyl)-
2-phenyloxazolidin-4-one (173n): General procedure A 
was followed employing 184 mg of N-nosyl oxaziridine 
(0.600 mmol, 1 equiv), 24.0 mg of TMSQn (0.120 mmol, 20 mol %), 0.21 mL of N,N-
diisopropylethylamine (1.2 mmol, 2 equiv), and 0.18 mL of cyclohexylacetyl chloride (1.2 
mmol, 2 equiv).  The crude product was purified via flash chromatography (6% EtOAc in 
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hexanes) to yield 73.4 mg (29%) of the compound as a mixture of two diastereomers.  Effective 
separation of these two diastereomers could be achieved by using MPLC for characterization 
purpose. Full characterization of the syn compound: [] 19D −63.9 (c 2.19, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  8.18 (d, J= 9.2 Hz, 2H), 7.71 (d, J= 8.8 Hz, 2H), 7.45 (t, J= 7.2 Hz, 1H), 7.35 (t, 
J= 7.2 Hz, 2H), 7.28-7.25 (m, 2H), 6.54 (d, J= 1.6 Hz, 1H), 4.38 (dd, J= 4.0, 1.6Hz, 1H), 1.93-
1.85 (m, 1H), 1.79-1.77 (m, 3H), 1.71-1.61 (m, 2H), 1.37-1.14 (m, 5H);  13C NMR (100 MHz, 
CDCl3):  170.1, 150.7, 143.1, 136.7, 130.4, 129.4, 128.8, 127.4, 123.8, 91.7, 81.7, 41.0, 28.5, 
26.5, 25.9, 25.8, 25.7; IR max
 
cm
-1
: 2929, 2855, 1754, 1534, 1456, 1403, 1383, 1350, 1314, 
1230, 1181, 1107, 1088, 856, 740; HRMS (ES+) m/z cald for C21H23N2O6S (M+H)
+
: 431.1277; 
found: 431.1268; Full characterization of the anti compound: [] 19D  +1.85 (c 1.35, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  8.21 (d, J= 8.8 Hz, 2H), 7.69 (d, J= 9.2 Hz, 2H), 7.48 (t, J= 7.6 Hz, 
1H), 7.36 (t, J= 7.6 Hz, 2H), 7.32-7.27 (m, 2H), 6.38 (d, J= 1.2 Hz, 1H), 4.27 (d, J= 3.6, 1.6 Hz, 
1H), 1.96-1.88 (m, 1H), 1.82-1.73 (m, 3H), 1.67-1.64 (m, 1H), 1.57-1.54 (m, 1H), 1.39-1.09 (m, 
5H);  13C NMR (100 MHz, CDCl3):  169.8, 150.7, 143.8, 135.4, 130.6, 129.0, 128.5, 128.4, 
124.0, 90.4, 81.5, 39.2, 28.8, 26.8, 26.0, 25.8; IR max
 
cm
-1
: 2929, 2855, 1757, 1534, 1458, 1384, 
1350, 1314, 1289, 1218, 1181, 1089, 1026, 855, 740; HRMS (ES+) m/z cald for C21H23N2O6S 
(M+H)
+
: 431.1277; found: 431.1267; The ee (>98%) was determined by chiral HPLC employing 
the anti diastereomers.  Daicel Chiracel
TM
 OD-H column, flow rate 1.0 mL/min, 10% 
i
PrOH/90% hexanes, Tr: 19.0 min (2R, 5S), 21.0 min (2S, 5R). 
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(S)-(+)-Methyl mandelate (177): To a stirred solution of oxazolidinone 173a (84.9 mg, 0.200 
mmol, 1 equiv) in 2 mL of MeOH was added 2 mg of MeONa (0.2 equiv, 0.04 mmol) at 0 °C.  
The resulting mixture was stirred at this temperature for 2h and then warmed to ambient 
temperature and stirred overnight.  After full consumption of 173a which could be monitored by 
TLC, 2 mL of HCl in MeOH (5%) was added into the reaction to hydrolyze the imine byproduct.  
The resulting mixture was stirred for 10 min at ambient temperature and diluted with EtOAc and 
washed with water.  The organic layer was separated and the aqueous layer was extracted 3x 
with EtOAc and the combined organic extracts were dried over MgSO4 and concentrated.  The 
crude material was purified via flash chromatography (20% EtOAc in hexanes) to yield 23 mg 
(70%) of the titled compound 177 as a wax solid.  [] 17D +173 (c 0.75, CHCl3); Separating the 
enantiomers by GLC [flow rate 3.5 mL/min, method: 80 C for 10 min, ramp @ 0.5 C/min to 
130 C, hold for 5 min; Tr: 59.9 min (R), 61.8 min (S)] provided the enantiomer ratio S : R = 4.0 : 
96.0 (92% ee). 
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(S)-S-Ethyl Hydroxy-phenyl-thioacetate (178):
68
 To a 0 °C solution of EtSH (17.8 µL, 1.2 
equiv, 0.240 mmol) in 2 mL of THF was added KHMDS solution (0.48 mL, 0.5 M in toluene, 
0.24 mmol).  The reaction was stirred for 5 min at 0 °C and then warmed to ambient temperature 
and stirred for another 15 min.  The resulting milky mixture was cooled to 0 °C and a solution of 
oxazolidinone 173a (84.9 mg, 1 equiv, 0.200 mmol) in 1 mL of THF was added dropwise.  The 
resulting mixture was stirred for 4h at 0 °C and warmed to ambient temperature and stirred for 
another 0.5h.  3 ML of HCl in MeOH (5%) was added into the reaction and stirred for 10 min.  
The solvent was removed by rotary evaporator and the residue was dissolved in EtOAc and 
washed with H2O.  The organic layer was separated and the aqueous layer was extracted 3x with 
EtOAc.  The combined organic extracts were dried (MgSO4) and concentrated.  The crude 
material was purified by flash column chromatography (14% EtOAc in hexanes) to yield 28 mg 
(72%) of the titled compound 178 as a clear wax.  The ee (>98%) was determined by chiral 
HPLC and only single enantiomer was observed.  Daicel Chiracel
TM
 OD-H column, flow rate 0.6 
mL/min, 10% 
i
PrOH/90% hexanes, Tr: 12.3 min (S), 17.6 min (R). 
 
 
 
(S)-(+)-Methyl mandelamide (179):
69
 NH3 gas was bubbled into 5 mL of MeOH at 0 °C for 20 
min. A solution of oxazolidinone 173a (84.9 mg, 0.200 mmol, 1 equiv) in 1 mL of CH2Cl2 was 
cannulated into the NH3/MeOH solution.  The reaction was stirred for another 5 min and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(5% MeOH in CH2Cl2) to yield 25 mg (83%) of the titled compound 179 as a white wax solid.  
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[] 17D +56.7 (c 1.20, EtOH).  The optical rotation is identical to the reported value of (S)-(+)-
methyl mandelamide, indicating an excellent ee of the ring opened product 179.
 
 
 
 
(S)-N-Mandeloylmorpholine (180):
70
 To a stirred solution of oxazolidinone 173a (84.9 mg, 
0.200 mmol, 1 equiv) and DMAP (14.4 mg, 0.100 mmol, 0.5 equiv) in 2mL of THF was added 
morpholine (0.17 mL, 2.0 mmol, 10 equiv) dropwise at ambient temperature.  The reaction was 
stirred overnight.  The reaction was diluted with CH2Cl2 and quenched with saturated NH4Cl 
aqueous solution.  The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 three times.  The combined organic extracts were dried (MgSO4) and concentrated.  The 
crude material was purified by flash column chromatography (1/1, EtOAc/Hexanes) to yield 39.8 
mg (90%) of the titled compound 180 as white solid. [] 15D  +3.96 (c 1.01, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  7.40-7.23 (m, 5H), 5.19 (d, J= 6.4 Hz, 1H), 4.72 (d, J= 6.4 Hz, 1H), 3.82-3.77 
(m, 1H), 3.73-3.67 (m, 1H), 3.64-3.60 (m, 1H), 3.58-3.53 (m, 1H), 3.47 (ddd, J= 3.2, 5.6, 11.6 
Hz, 1H), 3.30 (ddd, J= 2.8, 7.2, 13.2 Hz, 1H), 3.16 (ddd, J= 2.8, 5.6, 13.2 Hz, 1H), 3.07 (ddd, J= 
2.8, 7.2, 10.8 Hz, 1H);  13C NMR (100 MHz, CDCl3):  170.9, 139.1, 129.1, 128.7, 127.3, 71.5, 
66.5, 65.7, 45.2, 43.1; IR max
 
cm
-1
: 3408, 1643, 1452, 1399, 1272, 1251, 1114, 1068, 1029, 702.  
The ee (5%) was determined by Trost ester analysis upon converting amide 180 to 187.  
1
H 
NMR of 187 showed a 1:0.9 ratio of diastereomers and therefore the ee of 180 was 5%.    
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